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Previous research has suggested that lobeline, a plant alkaloid derived from 
Lobelia inflate, has potential to be an efficacious pharmacotherapy for the treatment 
of methamphetamine dependence.  In addition to attenuating methamphetamine-
induced dopaminergic alterations in vitro, lobeline has been shown to decrease the 
primary rewarding effects and discriminative stimulus properties of 
methamphetamine in rats.  It is of clinical interest to assess the utility of lobeline to 
decrease methamphetamine conditioned cues as these cues have been shown to 
significantly contribute to relapse.   
 
The current studies assessed the ability of lobeline to block the acquisition 
and expression of methamphetamine-induced conditioned place preference in rats.  
Lobeline blocked the acquisition of methamphetamine-induced conditioned place 
preference when a low dose of methamphetamine was used during conditioning.  
However, this blockade was surmounted with higher doses of methamphetamine.  
Furthermore, the expression of methamphetamine-induced conditioned place 
preference is attenuated following repeated administration, indicating that lobeline 
not only blocks the primary reinforcing effects of methamphetamine, but it also 
blocks the environmental cues that become associated with drug administration.  
These results provide further evidence that lobeline may be an efficacious treatment 
for methamphetamine dependence. 
 
The rewarding properties of psychostimulants are thought to be mediated, at 
least in part, by the nucleus accumbens shell.  The effects of lobeline on 
methamphetamine-induced alterations in this dopaminergic region were assessed 
using microdialysis in rats.  Acute lobeline did not have an effect on the 
methamphetamine-induced increases in dopamine, indicating that repeated lobeline 
administration may be more efficacious.  Interestingly, lobeline potentiated the 
methamphetamine-induced decrease of the dopamine metabolite, DOPAC.  These 
results suggest that acute lobeline may function to redistribute vesicular dopamine 
pools within the terminal bouton. 
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 1 
CHAPTER ONE 
 Introduction 
 
 Methamphetamine Dependence: Current Trends and Treatments. 
The negative impact that methamphetamine availability has had on our 
society is far-reaching.  Methamphetamine is commonly synthesized in clandestine 
laboratories using extremely caustic chemicals, which can readily create dangerous 
situations including environmental contamination, explosions, and fires.  Mere 
exposure to these laboratories can result in negative health consequences.  
However, the health consequences apparent in individuals that habitually use 
methamphetamine can be devastating as these individuals are at increased risk for 
unsafe sexual behaviors, cardiovascular problems, convulsions, and potentially 
long-lasting psychotic behavior (NIDA, 2007b).   
Despite efforts to curb methamphetamine production and use, a 2007 
telephone survey of 500 county law enforcement officers (sheriffs) from 43 states 
indicated that 47.5% of the sheriffs surveyed reported methamphetamine as the 
most problematic drug of abuse in their county (NACO, 2007).  While the number of 
methamphetamine laboratories seized by officials peaked in 2003 and has steadily 
decreased in recent years, the availability of methamphetamine has not decreased 
as evidenced by 80% of the sheriffs surveyed reporting that the availability of the 
drug has remained the same or increased in the last year (DEA; NACO, 2007).  
Although the stereotypic methamphetamine abuser is a white male between 18 and 
30 yrs old, an increased number of adolescents, women and ethnic minorities are 
using methamphetamine (NACO, 2007).  Additionally, recent reports from NIDA’s 
2006 Monitoring the Future Survey indicate that crystal methamphetamine use 
among young adults has not decreased over the last four years (NIDA, 2007a).  
These epidemiological data illustrate the persistent use of methamphetamine in the 
United States.     
Currently, there are few options available for treating methamphetamine 
dependence.  Participation in behavioral therapies such as contingency 
management programs have been shown to promote abstinence above that of 
standard or no treatment (Prendergast, Podus, Finney, Greenwell, & Roll, 2006; 
Roll et al., 2006; Shoptaw et al., 2005).  In addition to behavioral therapies, efforts 
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have been underway to identify an efficacious pharmacotherapy to aid in treating 
methamphetamine dependence.  A recent review highlights possible approaches 
that may be utilized in the development of a pharmacotherapy including 
immunotherapy and novel medications that would alter methamphetamine 
pharmacodynamics (Vocci & Appel, 2007).  Potential therapeutic targets include the 
vesicular monoamine transporter, the dopamine transporter, dopamine receptors, 
as well as GABA(Gamma-aminobutyric acid)ergic, glutamatergic, serotinergic, 
endogenous opioid, and endocannabinoid pathways (Vocci & Appel, 2007).  
Identification of a useful pharmacotherapy to aid in treating physiological alterations 
that result from methamphetamine dependence may allow for better outcomes 
following behavioral therapies (Ling, Rawson, Shoptaw, & Ling, 2006).  Research 
efforts to identify and develop an efficacious pharmacological aid for the treatment 
of methamphetamine dependence are ongoing.  
 
Pharmacokinetics of Methamphetamine 
Rodent models are often employed to study various neurochemical and 
behavioral aspects of psychoactive substance administration and have afforded an 
improved understanding of potential mechanisms underlying the rewarding effects 
of methamphetamine.  In rodent models, psychoactive drugs are typically 
administered intravenously, subcutaneously or intraperitoneally.  While humans 
administer methamphetamine intravenously, it is also commonly administered 
intranasally and by inhalation of the smoke that results from heating it.  In rats, the 
plasma concentration of methamphetamine (3 mg/kg) reaches a maximum level 
faster following intraperitoneal (5 – 10 min) administration than following 
subcutaneous administration (20 – 30 min); however, ~42 % of methamphetamine 
administered via intraperitoneal injection is subject to first-pass metabolism 
(bioavailability ~52 %), whereas the bioavailability is 100% following intravenous 
and subcutaneous injection (Gentry et al., 2004).  While intravenous administration 
provides 100% bioavailability in humans, the bioavailability of methamphetamine is 
lower with other routes of administration, such as intranasal (79%) and smoked 
(67%; Harris et al., 2003).  Following a single administration of methamphetamine 
that results in equivalent peak plasma concentrations in rat and human, the 
elimination half-life is ~70 min and ~ 12 hr, respectively (Cho, Melega, Kuczenski, & 
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Segal, 2001; Cook et al., 1993).  Although most of the information available on 
methamphetamine pharmacokinetics is derived from male subjects, there is 
evidence that there are sex differences in methamphetamine serum levels achieved 
following intravenous administration in rats; further characterizations of sex 
differences with regard to pharmacokinetics warrants further investigation given the 
increased use among women (Milesi-Halle, Hendrickson, Laurenzana, Gentry, & 
Owens, 2005).  Differences in the bioavailability of a methamphetamine across 
routes of administration and the faster elimination of drug in rodents compared to 
human should be taken into careful consideration when evaluating findings from 
preclinical research.   
 
Mechanisms of Drug Dependence 
Theoretical Framework  
The processes involved in learning and memory make it possible for an 
individual to survive in their environment.  One theoretical framework for drug 
addiction suggests that the neurochemical consequences of psychoactive drug 
administration may result in maladaptive learning.  Associations learned during 
repeated drug administration result in a distinct behavioral pattern involving an 
incredibly high motivation to obtain drugs and an inability to abstain from 
administering them, despite health and social consequences (Di Chiara, 1999; 
Hyman & Malenka, 2001).  There are several dissociable types of learning that are 
affected by repeated exposure to psychostimulants, including associative 
(instrumental and classical conditioning), non-associative (habituation and 
sensitization), and procedural (skills and habits).  Many of these learning processes 
rely on the same neurobiological mechanisms that are altered following exposure to 
psychoactive substances.  It has been suggested that the milieu of drug-induced 
neurobiological alterations ultimately results in abnormal, maladaptive reward-
related learning (Kelley, 2004).  Investigating the interactions of psychostimulant-
induced neurobiological changes and reward learning may afford an efficacious 
treatment for drug dependence that includes synergistic behavioral and 
pharmacological interventions. 
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Neuroanatomical and Neurochemical Aspects of Methamphetamine 
Dependence 
Techniques 
Decades of research have provided insight into the neurobiological 
mechanisms of learning that are thought to be altered following exposure to 
psychoactive substances by utilizing various in vitro and in vivo methodologies.  For 
instance, anatomical lesions or inactivation of particular neurotransmitter systems 
within a specific brain region prior to evaluation of a behavioral response can 
provide information on the importance of that region for various behaviors and/or 
neurotransmitter levels in other interconnected brain areas.  Retrograde and 
anterograde labeling of neurons has characterized neuronal pathways from one 
brain region to another, as well as connections within specific brain structures.  In 
addition, receptor binding techniques can be used to identify and quantify specific 
receptor subtypes distinct to specific brain regions.  Electrically or pharmacologically 
evoked neurotransmitter release can be assessed in several different assays and 
provides insights into endogenous neuronal responses.  Analysis of 
neurotransmitter levels from dissected brain tissue or microdialysis samples using 
high performance liquid chromatography with electrochemical detection (HPLC-EC) 
has provided useful information about neurotransmitter levels within specific brain 
regions following pharmacological and behavioral manipulations. Using receptor 
selective agonists and antagonists in combination with these techniques can reveal 
detailed information on the contribution of specific neurotransmitter systems or 
receptor subtypes on the rewarding effects of a psychoactive drug.   
 In vivo microdialysis has provided a wealth of information about phasic levels 
of monoamines in the mesocorticolimbic pathways in response to psychoactive 
drugs.  With this technique, rodents are implanted with a guide cannula and stylet 
that terminates a few millimeters dorsal to the brain region of interest using 
stereotaxic surgical techniques.  Following 5-7 days of recovery, a microdialysis 
probe, which snaps into the guide cannula, is implanted 4-24 hr prior to an 
experimental manipulation.  The probe has an inlet and outlet tube that allows 
perfusion of artificial cerebrospinal fluid into and dialysate fluid out of a specified 
brain region, usually at a rate of ~1 µl/min.  At the end of the plastic probe is a 2 
mm, semi-permeable membrane across which only small (up to 30 kD) endogenous 
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molecules can diffuse.  Before the experimental manipulation begins, the 
concentration of molecules inside and outside (i.e. the extracellular space) of the 
probe reach equilibrium as a result of diffusion down their concentration gradient 
(Zhang & Beyer, 2006).  The dialysate fluid is collected at set time intervals (usually 
20 min) following an experimental manipulation and subsequently analyzed using 
high HPLC-EC.  Since baseline samples are collected for each animal, 
experimental data is generally represented as a percent of baseline and the amount 
of neurotransmitter represented is derived from external standards.  In order to 
determine the actual concentration of the analyte of interest in vivo, a quantitative 
microdialysis technique known as no-net-flux is often used (Parsons & Justice, 
1994).  With this method, several concentrations of the analyte of interest are 
perfused through the microdialysis probe and the dialysate samples are then 
analyzed.  The concentration at which the perfusate and the dialysate are equal is 
the point of no-net flux, which estimates the concentration of the analyte in the 
extracellular space (Watson, Venton, & Kennedy, 2006). 
By analyzing the microdialysis samples with HPLC-EC, the concentration of 
catecholamines, in addition to several other endogenous molecules, can be 
determined.  In this assay, the microdialysis sample can be introduced via injection 
into the mobile phase, which is continuously pumped under pressure through a 
stationary phase, or column, where the analytes of interest are eluted based on 
their interactions with these two phases.  The mobile phase then carries the 
analytes to the electrochemical detector where a potential is applied and the 
analytes are oxidized or reduced and the resulting free electron is recorded as a 
change in current, which can be further characterized by computer software.  Due to 
the sample volume required for analysis with HPLC-EC, usually ~20 µl, 
microdialysis with HPLC-EC is useful when assessing an overall increase in 
monoamine levels across 20 min; however, the temporal resolution does not allow 
for sec-by-sec analysis of neurochemical changes as can be obtained with 
voltammetry (Westerink, 1995).  However, information provided by voltammetry 
experiments does not provide the level of sensitivity provided by HPLC-EC 
(Westerink, 1995).  Combinations of the aforementioned techniques in preclinical 
research designs can provide useful insights into the neurochemical mechanisms 
underlying the addictive properties of psychostimulants. 
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Neurocircuitry and Neurotransmitter Systems 
Specific anatomical locations in brain have been associated with the primary 
reinforcing effects of psychostimulants and reward-related learning including: (1) the 
nucleus accumbens, which is an important region for reward and motor integration; 
(2) the ventral tegmental area, which is activated by reward and unpredicted events; 
(3) the prefrontal cortex, which is employed for executive function, impulse control, 
and decision making; (4) the ventral pallidum, which regulates voluntary motor 
output; (5) the amygdala, which is essential for emotional processing and reward 
learning; and (6) the hippocampus, which is critical for memory and detecting 
novelty (Bardo, 1998).  These brain regions communicate with one another through 
various pathways (Ikemoto, 2007; Kalivas & O'Brien, 2007; Kelley, 2004; Kelley & 
Berridge, 2002).  Dopaminergic cell bodies within the ventral tegmental area project 
axons to several forebrain regions including the prefrontal cortex, nucleus 
accumbens, and the basolateral amygdala. The prefrontal cortex in turn sends 
glutamatergic input back to the ventral tegmental area and to the nucleus 
accumbens, an area that also receives glutamatergic input from the basolateral 
amygdala and the hippocampus.  This circuitry has been implicated as playing a 
major role in reward-related learning, decision making, and memory.  In addition, 
glutamate is thought to modulate midbrain dopamine neurons, as stimulation of 
glutamatergic afferents from the pedunculopontine tegmental nucleus increase 
burst firing in A9 (substantia nigra) dopaminergic neurons (Lokwan, Overton, Berry, 
& Clark, 1999).  Within the midbrain, GABA afferents from striatonigral neurons 
cause inhibition of dopamine neuron activity (Grace & Bunney, 1985).  Furthermore, 
when acute methamphetamine (0.15 mg/kg, i.v.) is administered to human subjects, 
functional magnetic resonance indicates significant activation of the medial 
orbitofrontal cortex, anterior cingulate cortex (rostral portion), and ventral striatum 
(Vollm et al., 2004).  The interactions of dopaminergic and glutamatergic signaling 
are critical for reward-related learning and play a role in drug-induced neuronal 
plasticity, in part due to the co-localization of receptors in medium spiny neurons of 
the striatum (Berke & Hyman, 2000; Kelley, 2004; Smith & Bolam, 1990).  While 
dopamine signaling appears to be important for detecting unexpected 
reinforcement, as well as motivation and incentive, the glutamatergic signal is 
important for sensory/motor processing (Kelley, 2004).   
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In addition to glutamate, a number of other neurotransmitters are known to 
modulate mesocorticolimbic dopamine system, including acetylcholine.  
Acetylcholine is the endogenous neurotransmitter that activates nicotinic and 
muscarinic receptors.  There are two major cholinergic systems in brain, one  that 
arises in the basal forebrain and projects to the cortex and hippocampus and 
another that arises in the pedunculopontine tegmentum which sends ascending 
projections to the thalamus and midbrain areas, including the substantia nigra and 
ventral tegmental area (Dani & De Biasi, 2001).  Importantly, activation of the 
nicotinic receptors that are expressed on presynaptic dopamine neurons can lead to 
increased neuronal firing in dopaminergic pathways (Dani & De Biasi, 2001).                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Dopamine that is released from the presynaptic terminal into the synapse 
diffuses and interacts with both pre and postsynaptic targets. The dopamine 
receptors are classified as either D1 or D2-like and are G-protein coupled receptors.  
D2 receptors function mainly as presynaptic autoreceptors.  Stimulation these 
receptors results in a decreased firing rate and diminished dopamine output from 
the nerve terminal, while antagonism of the presynaptic D2 receptors results in 
increased dopamine synthesis and release (Grace, 2002).  Activation of D2 
receptors results in the inhibition of adenylate cyclase, which subsequently reduces 
the phosphorylation of cAMP-regulated phosphoprotein of 32,000kDa (DARPP-32; 
Cooper et al., 2003).  When DARPP-32 phosphorylation is reduced, the resulting 
decrease in protein phosphatase 1inhibition leads to the dephosphorylation of 
several proteins and ultimately inhibition of neurotransmitter release (Cooper et al., 
2003).  The D1 receptors are primarily located on postsynaptic dendrites.  Activation 
of these receptors results in an increase in adenylate cyclase, which subsequently 
increases the phosphorylation of DARPP-32 (Cooper et al., 2003).  Increased 
phosphorylation of DARPP-32 results in potent inhibition of protein phosphatase 1, 
which interacts with intracellular signaling mechanisms thought to underlie synaptic 
plasticity.  
In addition, extracellular dopamine interacts with the dopamine transporter, 
which functions normally as a reuptake mechanisms allowing dopamine to be taken 
back into the presynaptic nerve terminal (Cooper, 2003).  Once dopamine is taken 
back into the presynaptic nerve terminal, it is sequestered in vesicular membranes 
which protect it from oxidation by monoamine oxidase.  The vesicular monoamine 
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transporter is a protein located in the synaptic vesicular membrane and is 
responsible for transporting dopamine into the vesicles.  Within dopamine neuron 
terminals, the vesicular monoamine transporter also plays an important role in 
mediating dopamine release (Schuldiner, 1994).   
Methamphetamine is a derivative of amphetamine and has a very similar 
pharmacology (Melega, Williams, Schmitz, DiStefano, & Cho, 1995).  
Amphetamines have several molecular targets including: 1) the dopamine 
transporter; 2) monoamine oxidase activity; and 3) the vesicular monoamine 
transporter (Mantle, Tipton, & Garrett, 1976; Seiden, Sabol, & Ricaurte, 1993).  
Amphetamines enter the neuronal cytoplasm by diffusing across the bi-lipid layer 
and acting as substrates for the dopamine transporter.  Once inside, amphetamine 
inhibits the vesicular monoamine transporter from sequestering dopamine into 
vesicles and induces the reverse transport of cytosolic dopamine by the dopamine 
transporter (Ary & Komiskey, 1980; Brown, Hanson, & Fleckenstein, 2000; Liang & 
Rutledge, 1982; Philippu & Beyer, 1973; Sulzer et al., 1995).  In addition to 
inhibition of the vesicular monoamine transporter, methamphetamine enters the 
vesicles which results in an altered pH gradient (“weak base” effect) that further 
decreases the sequestration of neurotransmitter into vesicles (Sulzer et al., 1995).  
Since amphetamine inhibits monoamine oxidase from metabolizing dopamine, the 
increased amount of cytosolic dopamine available for amphetamine-induced 
reverse transport results in an increase in extracellular dopamine and a decrease in 
the dopamine metabolite DOPAC in the terminal and cell body regions of midbrain 
dopamine neurons (Dwoskin & Crooks, 2002; Mantle et al., 1976).   
A few differences between the neurochemical actions of amphetamine and 
methamphetamine are emerging.  For example, amphetamine has been shown to 
be more effective than methamphetamine at increasing extracellular dopamine 
concentrations in the PFC; however amphetamine and methamphetamine exhibit 
similar efficacy at increasing extracellular dopamine concentrations in the nucleus 
accumbens (Shoblock, Maisonneuve, & Glick, 2003).  In addition, while the 
norepinephrine transporter functions in concert with the dopamine transporter to 
remove dopamine from the synapse following its release, amphetamine has a 
higher binding affinity than methamphetamine for the norepinephrine transporter.  
As a result, amphetamine is able to block the reuptake of and reversal of both the 
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norepinephrine and the dopamine transporter, while methamphetamine blocks 
primarily the dopamine transporter (Shoblock, Maisonneuve, & Glick, 2004).  
Therefore, by acting through an additional mechanism, amphetamine administration 
results in a greater concentration of extracellular dopamine in the mPFC than is 
produced by methamphetamine.  
 
Behavioral Aspects of Drug Dependence 
Operant Conditioning 
Individuals engage in many behaviors that have specific, reliable outcomes, 
such as feeling satiated after eating; if the outcome resulting from a particular 
behavior subsequently leads to an increase of that behavior, that outcome is said to 
be reinforcing (Koob, 1992).  Operant conditioning principles are used in animal 
models to assess the reinforcing effects of drugs.  Typically, animals are prepared 
with an indwelling jugular catheter and trained to emit a response (i.e. pressing a 
lever) in order to receive an infusion of a psychoactive drug.  Most drugs that are 
abused by humans are also self-administered by rodents (Gardner, 2000; Koob, 
1992).  This model allows for the preclinical assessment of interventions that will 
potentially decrease drug-taking behavior.  Behaviors that are reinforced, including 
those that are biologically relevant, such as eating and engaging in sex, as well as 
those that lead to the administration of psychoactive drugs, increase dopaminergic 
neuronal activity in a number of structures and pathways (Kelley, 2004).   
Both d and l-isomers of methamphetamine are self-administered by rats 
(Pickens, 1967; Yokel & Pickens, 1973).  The mesolimbic dopaminergic pathway is 
critically involved in amphetamine self-administration, as dopamine agonists such 
as apomorphine and piribedil decrease drug intake, whereas dopamine antagonists 
such as (+)-butaclamol induce periods of increased drug intake (Yokel & Wise, 
1976, 1978).  This increase in responding likely reflects attenuation of the rewarding 
effect of the drug, prompting the animal to increase operant responding to 
compensate for the decreased drug effect.  Lesions of the nucleus accumbens also 
result in attenuation of amphetamine self-administration, further demonstrating a 
critical role of this part of the circuitry in drug reward (Lyness, Friedle, & Moore, 
1979). 
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Pavlovian Conditioning 
Pavlovian, or classical conditioning, is a form of associative learning that is 
also important for aspects of drug dependence.  In classical conditioning, a 
temporal contingency is arranged between two stimuli such that one stimulus (the 
conditioned stimulus) reliably predicts the occurrence of a second stimulus (the 
unconditioned stimulus; Siegel, 1977).  Prior to any pairings with the unconditioned 
stimulus, the conditioned stimulus typically does not elicit a physiological response.  
Presentation of the unconditioned stimulus alone will produce a physiological 
response in an organism, which is known as the unconditioned response.  However, 
following repeated pairings of the conditioned stimulus with the unconditioned 
stimulus, presentation of the conditioned stimulus alone will come to elicit a 
physiological response known as the conditioned response.  Pavlov (1927) was first 
to demonstrate that a psychoactive drug is able to function as an unconditioned 
stimulus.  After repeatedly pairing the systemic effects of a psychoactive drug 
(unconditioned stimulus) with a tone (conditioned stimulus), presentation of the tone 
alone produced a physiological response similar to the drug action (Pavlov, 1927).  
These principles can be used to understand the conditioned stimulus-reward 
associations that are observed following repeated drug administration.     
In humans, exposure to environmental stimuli that have become associated 
with the psychoactive properties of a drug can, by themselves, elicit conditioned 
responses that often lead to intense craving and relapse (O'Brien, Childress, & 
McLellan, 1991; Stewart, 1992).  When detoxified cocaine users were shown 
videotapes of simulated cocaine use, they reported cocaine craving (Childress et 
al., 1999).  Concurrent positron emission tomography (PET) assessed in this study 
indicated that subjects also displayed increased regional cerebral blood flow, an 
indicator of increased neuronal activity, in limbic regions, including the amygdala 
and anterior cingulate (Childress et al., 1999).  Furthermore, when cocaine-
dependent males were read a script of autobiographical drug-related events, 
neuronal activation was observed in the amygdala, anterior cingulate, and nucleus 
accumbens (Kilts et al., 2001).  More recent studies have revealed that exposure to 
conditioned stimuli in cocaine and amphetamine-dependent individuals results in 
increased dopamine release in striatal regions (Boileau et al., 2007; Volkow et al., 
2006).  These studies illustrate that conditioned cues cause neurophysiological 
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changes in brain regions important for reward-related learning and the formation of 
stimulus-reward associations. 
 
Non-Associative Learning 
While both operant and Pavlovian conditioning processes are important for 
understanding drug addiction, non-associative mechanisms also play a role.  It has 
long been recognized that repeated administration of a psychostimulant induces an 
enduring increase in locomotor activity and at least some of this change is due to 
non-associative learning.  Induction and expression of sensitization in an animal 
model is thought to reflect changes that occur in the process of human drug 
addiction (White & Kalivas, 1998).  Thus, there has been a focused effort to fully 
characterize the neurobiological mechanisms involved in learning and memory 
because these mechanisms are thought to underlie the maladaptive behavioral 
patterns associated with acquiring, ingesting, and craving psychoactive substances 
(Kelley, 2004).   
 
Conditioned Place Preference 
 Conditioned place preference (CPP) is an increasingly utilized paradigm that 
is used to assess the rewarding properties of psychoactive drugs (for review Bardo 
& Bevins, 2000; Tzschentke, 1998, 2007).  Following repeated administration of a 
psychoactive drug with a previously neutral environment, the cues associated with 
that environment will take on secondary rewarding characteristics (i.e. the cues 
become conditioned).  Once this conditioning has occurred, exposure to the 
conditioned cues results in approach behavior.  This paradigm is well characterized 
for many drugs of abuse and there are insights into the neuroanatomical regions 
involved in this type of learning that have been derived from microinfusion and 
lesioning studies (McBride, Murphy, & Ikemoto, 1999; Sellings & Clarke, 2003; 
Tzschentke, 2007).   
There are several variations in protocols used for CPP studies. Typically, a 
three-compartment apparatus is used in which two larger end compartments are 
connected with a smaller center compartment.  All three compartments are distinct 
(i.e. varying in color, floor texture, odor, etc.) and guillotine doors allow access to all 
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three compartments or confinement to one of the end compartments.  The three 
phases that take place during a typical CPP experiment are: (1) preconditioning 
test, (2) conditioning phase, and (3) postconditioning test.  During the 
preconditioning test, animals are allowed free access to all three compartments and 
time spent in each is recorded.  In an unbiased design, animals show no preference 
for any of the experimental compartments during the preconditioning test as 
measured by the time spent in each of the compartments.  Animals are then 
assigned randomly to an experimental group, and which end compartment will 
serve as the “drug-paired” compartment is counterbalanced across all the animals.  
In contrast, when animals show a preference for one of the end compartments 
during the preconditioning test and the opposite end compartment (the non-
preferred side) serves as the “drug-paired” compartment during conditioning trials, 
the design is said to be biased.  The biased design is used less often as the 
interpretation of the results derived from using this design is sometimes problematic 
(Bardo & Bevins, 2000; Tzschentke, 2007).   
Next, during the conditioning phase, animals undergo an experimental 
manipulation prior to being confined to one of the end compartments during one 
session and undergo a control session prior to being placed in the opposing end 
compartment in a separate session.  Typically, the experimental and control 
manipulations are conducted on alternating days.  Following completion of the 
conditioning phase, animals undergo the postconditioning test where they are once 
again allowed free access to the entire apparatus and time spent in each 
compartment is assessed.  If significantly more time is spent in the compartment 
paired with the experimental manipulation than that paired with the control condition 
or than the time spent in that compartment during the preconditioning test, that 
manipulation induces a place preference.  If significantly less time is spent in the 
compartment paired with the experimental manipulation than that paired with the 
control condition or than time spent in that compartment during the preconditioning 
test, that manipulation induces a place aversion.  Two separate aspects of CPP can 
be assessed, acquisition and expression.  During a test of acquisition, animals are 
conditioned as described above and the animal undergoes the postconditioning test 
in a drug-free state.  Experimental manipulations in this type of design always occur 
prior to or during the conditioning phase.  Alternatively, during a test of expression 
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animals are conditioned as described above and administered an experimental 
manipulation (i.e. potential pharmacotherapy), prior to the postconditioning test.  
There are several acceptable ways in which to report results from CPP 
experiments using an unbiased design.  The most straightforward method is to 
compare the time spent (sec) in the previously drug-paired versus saline-paired 
compartments.  Alternatively, a difference score for each group can be calculated 
by subtracting the time spent (sec) in the previously saline-paired compartment from 
the time spent in the previously drug-paired compartment.  This latter method 
provides a single number for each experimental group which is advantageous when 
assessing correlations between CPP data and another dependent variable, such as 
locomotor activity.  Another common approach is to calculate a preference ratio 
using the following equation: (time spent in drug paired compartment) / (time spent 
in drug + saline paired compartments).  This ratio provides an index of preference 
for the previously drug-paired compartment.   
As with any preclinical model of reward/reinforcement, there are advantages 
and disadvantages of the CPP paradigm, relative to the drug self-administration 
paradigm, (Bardo & Bevins, 2000; Van der Kooy, 1987).  The advantages of using 
CPP include: (1) observation of either a preference or an aversion following an 
experimental manipulation; (2) animals can be assessed for reward-related 
behavior while in a drug-free state, ensuring that any behavior exhibited is not due 
to drug-induced impairments; (3) given that animals do not typically have to undergo 
surgical procedures and the experimental sessions are not as time consuming, 
these experiments are more cost-efficient; and (4) two behaviors, locomotor activity 
and reward, can be assessed simultaneously.  There are several disadvantages as 
well, including: (1) difficulty in obtaining a graded dose-effect curve; (2) when using 
a biased design, it is difficult to determine if the testing apparatus is truly unbiased 
across studies, making the results ambiguous; and (3) a CPP paradigm for human 
subjects has not been developed.  It appears that the neurocircuitry underlying the 
classical conditioning processes that occur during CPP are distinct from those 
underlying the instrumental learning that occurs during drug self-administration 
(Bardo & Bevins, 2000).   
Amphetamine, as well as methamphetamine, has been shown to induce 
CPP.  The acquisition of amphetamine CPP is blocked by both D1 and D2 
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dopamine receptor antagonists, while only D1 receptor antagonism blocks the 
expression of amphetamine CPP (Hoffman & Beninger, 1989; Liao, Chang, & 
Wang, 1998; Spyraki, Fibiger, & Phillips, 1982).  Amphetamine infused directly into 
the nucleus accumbens results in CPP, an effect that is abolished by co-infusion of 
a D1 antagonist into the nucleus accumbens, as well as by a 6-hydroxydopamine 
lesion of the nucleus accumbens shell (Carr & White, 1983; Hiroi & White, 1991).  In 
addition to the nucleus accumbens, other brain regions in the limbic circuitry have 
been implicated in amphetamine-induced CPP.  Lesions of the cholinergic 
pedunculopontine tegmental nucleus block the acquisition of amphetamine CPP, 
while electrolytic lesions of the lateral nucleus of the amygdala block both 
acquisition and expression of amphetamine CPP (Olmstead & Franklin, 1994).  
Interestingly, while medial prefrontal cortex lesions block the acquisition of cocaine 
CPP, these lesions have no effect on amphetamine CPP (Tzschentke, 1998).  
Amphetamine CPP is also blocked by reserpine, a VMAT2 ligand that depletes 
vesicular stores of dopamine (Hiroi & White, 1990).  Thus, while acquisition and 
expression of amphetamine CPP can be affected differentially, dopaminergic 
neurotransmission in the nucleus accumbens plays a critical role for both. 
Locomotor activity during the conditioning phase of CPP experiments is 
reported frequently and it has been demonstrated that amphetamine-induced 
locomotor stimulation is not necessary for its rewarding properties (Carr, Phillips, & 
Fibiger, 1988).  Amphetamine sensitization has been shown to be, at least in part, 
dependent on contextual cues because the sensitized response is not observed if d-
amphetamine is administered in a novel environment (Anagnostaras & Robinson, 
1996).  Many neurotransmitter systems have been implicated in the process of 
sensitization, including dopamine, glutamate, and acetylcholine (White & Kalivas, 
1998).  
To what extent the outcomes of CPP, self-administration, and locomotor 
activity experiments assessing psychostimulant-induced behaviors are correlated is 
currently under debate.  Sensitization is thought to occur during the acquisition of 
psychostimulant self-administration (Schenk & Partridge, 1997).  While 
amphetamine-induced behaviors rely on the mesocorticolimbic dopamine pathway 
and often occur simultaneously, they are dissociable.   
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Lobeline as a Potential Pharmacotherapy for Methamphetamine Dependence 
Recently, it has been postulated that lobeline, an active alkaloid found in 
Indian tobacco (Lobelia inflata), may have potential as a pharmacotherapy for 
psychostimulant abuse (Dwoskin & Crooks, 2002).  Lobeline has a complex 
pharmacological profile.  This alkaloid has been classified historically as a nicotinic 
receptor agonist that binds more selectively to high than to low affinity nicotinic 
receptors in striatal preparations (Brioni, Decker, Sullivan, & Arneric, 1997; Decker, 
Majchrzak, & Arneric, 1993).  However, several lines of evidence now indicate that it 
acts as a functional nicotinic receptor antagonist.  In vitro studies have shown that 
lobeline inhibits [3H]overflow from superfused [3H]dopamine-preloaded striatal slices 
and acts as a functional antagonist as assessed in the rubidium efflux assay using 
thalamic synaptosomes (D. K. Miller, Crooks, & Dwoskin, 2000; Teng, Crooks, 
Sonsalla, & Dwoskin, 1997).  In vivo microdialysis experiments in nicotine 
pretreated rats (0.4 mg/kg, SC for 5 days) have demonstrated that systemic lobeline 
administration does not change extracellular levels of dopamine or 3, 4-
dihydroxyphenylacetic acid (DOPAC) in the nucleus accumbens core (Benwell & 
Balfour, 1998).  Furthermore, repeated administration of nicotine results in 
increased nicotinic receptor binding sites, whereas repeated administration of 
lobeline does not alter the affinity or number of nicotinic receptor binding sites (Bhat, 
Turner, Selvaag, Marks, & Collins, 1991).  Consistent with the neurochemical 
evidence that lobeline acts as a functional nicotinic receptor antagonist; 
administration of lobeline specifically attenuates the locomotor-stimulating effects of 
repeated nicotine administration (Miller et al., 2003).  Thus, evidence from both 
neurochemical and behavioral research strongly supports the view that lobeline is a 
functional antagonist at neuronal nicotinic receptors in the mesolimbic dopamine 
system.  
In addition to the aforementioned activity at neuronal nicotinic receptors, 
lobeline also interacts with the vesicular monoamine transporter to inhibit the 
sequestration of dopamine into vesicular stores (Teng, Crooks, & Dwoskin, 1998).  
It is thought that through this mechanism, lobeline has potential as a 
pharmacotherapy for methamphetamine dependence (for review see (Dwoskin & 
Crooks, 2002).  Lobeline pretreatment selectively inhibits amphetamine induced 
dopamine overflow in rat striatal slices as assessed in the endogenous dopamine 
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release assay (Miller et al., 2001). These in vitro experiments have indicated that in 
the presence of lobeline, presynaptic dopamine stores are redistributed, rendering 
dopamine unavailable for methamphetamine-induced reverse transport (Dwoskin & 
Crooks, 2002).  It is likely that lobeline attenuates the rewarding properties of 
methamphetamine through VMAT2 inhibition, although other mechanisms may also 
play a role. 
Lobeline may have potential as a pharmacotherapy for treating 
methamphetamine dependence (Dwoskin & Crooks, 2002; Zheng, Dwoskin, & 
Crooks, 2006).  Using a rodent model of methamphetamine self-administration, the 
potential of lobeline to decrease drug taking behavior was assessed (Harrod, 
Dwoskin, Crooks, Klebaur, & Bardo, 2001).  Male Sprague-Dawley rats were trained 
to lever press for sucrose reinforcement, underwent surgery to implant an indwelling 
jugular catheter, and were then trained to self-administer methamphetamine (0.05 
mg/kg/infusion) on a terminal fixed ratio 5 schedule of reinforcement.  A separate 
group of rats was trained to lever press for sucrose reinforcement on a terminal 
fixed ratio 5 schedule of reinforcement.  Once stable responding was reached in 
both assays, lobeline (0.3, 1.0 and 3.0 mg/kg, sc) pretreatments were administered.  
The highest dose of lobeline (3 mg/kg) resulted in an acute decrease of both 
methamphetamine infusions and sucrose pellets.  Additional experiments 
demonstrated that following 7 repeated administrations, lobeline (3 mg/kg) 
selectively decreased methamphetamine infusions as tolerance developed to the 
decrease in sucrose pellets earned (Harrod et al., 2001).  Further, increasing the 
unit dose of methamphetamine does not surmount the lobeline-induced decrease 
(Harrod et al., 2001).  While acute lobeline (3 mg/kg) administration prior to 
methamphetamine (1.0 mg/kg) did not specifically decrease methamphetamine-
induced reinstatement of methamphetamine-seeking behavior, an overall decrease 
in number of responses was observed (Harrod, Dwoskin, Green, Gehrke, & Bardo, 
2003).  However, given that lobeline (3 mg/kg) has been shown to non-specifically 
decrease operant behavior acutely, an effect that tolerates within four 
administrations, it is unknown if repeated lobeline administration would result in 
specific attenuation of methamphetamine-induced reinstatement of 
methamphetamine-seeking behavior.  It is also currently unknown if lobeline would 
decrease cue-induced reinstatement of methamphetamine-seeking behavior.  While 
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there are currently no reports on human studies assessing lobeline’s efficacy as a 
pharmacotherapy for methamphetamine dependence in a clinical population, 
research from preclinical models appear promising. 
Importantly, lobeline does not appear to have abuse liability.  In one study, 
four separate groups of male Sprague-Dawley rats were trained to lever press for 
sucrose reinforcement, implanted with a jugular catheter, and allowed to self-
administer either saline or one dose of lobeline (0.015, 0.05, 0.15 mg/kg/infusion; 
(Harrod et al., 2003).  None of the rats acquired self-administration of lobeline at 
any of the doses tested.  In addition, acute lobeline (1 and 3 mg/kg) does not 
reinstate extinguished methamphetamine-seeking behavior (Harrod et al., 2003).  
Further, lobeline administration repeatedly paired with a distinct environment does 
not induce a conditioned place preference (Fudala & Iwamoto, 1986).  These 
studies illustrate the utility of lobeline to inhibit reward-related behaviors induced by 
psychostimulants without functioning as a reinforcer when administered alone.  
As indicated previously, pharmacological manipulations can differentially 
affect the acquisition and expression of CPP.  While the effects of lobeline on 
acquisition of methamphetamine CPP can provide insight into potential mechanisms 
underlying the ability of lobeline to decrease methamphetamine reward, it is also 
clinically relevant to determine if lobeline attenuates the expression of 
methamphetamine CPP because a pharmacotherapy would be administered 
following previous exposure to a psychoactive substance.  Previous reports indicate 
that administration of lobeline alone does not elicit drug-seeking behavior in rats 
extinguished from methamphetamine-taking behavior (Harrod et al., 2003).  
However, there is currently no available information of the effect of lobeline on cue-
induced reinstatement of drug-seeking behavior.   
Since methamphetamine CPP can be disrupted by a variety of 
neuroanatomical and pharmacological manipulations, it is also of interest to assess 
the neurochemical profile of lobeline administration prior to methamphetamine in 
vivo.   Currently, the proposed mechanisms by which lobeline is decreasing 
methamphetamine reward are derived mostly from in vitro experiments.  Given the 
complexity of the limbic system pathways that are disrupted during tissue extraction, 
it is essential that these effects are confirmed by in vivo experiments.   
Copyright © Nichole Marie Neugebauer 2008
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CHAPTER TWO 
 Experiment 1 
  
Lobeline Attenuates the Acquisition of Methamphetamine-Induced 
Conditioned Place Preference and Locomotor Activity. 
 
The purpose of the first experiment was to assess if lobeline alters 
methamphetamine CPP in rats.  In contrast to self-administration, CPP is a model 
that assesses the role of conditioned contextual cues in drug reward.  In humans, 
exposure to environmental or contextual cues that are associated with drugs of drug 
through classical conditioning can elicit drug craving and relapse (O'Brien et al., 
1991).  When tested in a drug-free state, re-exposure to amphetamine-associated 
cues in healthy human volunteers increases dopaminergic transmission in the 
ventral striatum similar to the increase observed following amphetamine 
administration (IV) (Boileau et al., 2007; Drevets et al., 2001).  Since lobeline has 
been proposed to be a potential pharmacotherapy for methamphetamine 
dependence, the ability of lobeline to disrupt the conditioned associations that are 
formed by repeated pairings of methamphetamine with distinct contextual cues 
warrants examination.  In addition to assessing the effects of lobeline on 
methamphetamine CPP, the current preclinical study also measured locomotor 
activity during drug-conditioning trials.  It was hypothesized that lobeline would 
attenuate methamphetamine-induced hyperactivity and inhibit the acquisition of 
methamphetamine-induced CPP. 
 
Methods 
Subjects 
Male Sprague-Dawley rats (N=110, 225-250 g; Harlan Industries, 
Indianapolis, IN) were housed two per cage, with ad libitum access to food and 
water.  The colony room was maintained on a 12-hr/12-hr light/dark cycle and 
controlled for temperature and humidity. All animals were handled at least 5 min on 
each of the 3 days prior to commencement of the experiment. Experiments were 
conducted during the light phase.  All experimental protocols were conducted in 
strict accordance with the National Institutes of Health Guide for the Care and Use 
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of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at the University of Kentucky.  
 
Drugs 
Methamphetamine hydrochloride was obtained from the National Institute on 
Drug Abuse (Research Triangle Park, NC, USA).  Lobeline hemisulfate was 
purchased from ICN (Costa Mesa, CA). Doses of methamphetamine and lobeline 
were calculated as salt weight, were dissolved in 0.9% NaCl (saline) and were 
administered in 1 ml/kg volume.  Lobeline was administered via SC injection and 
methamphetamine was administered via IP injection.  
 
Apparatus 
CPP and locomotor activity were assessed using an automated, 3-
compartment apparatus operated via a computer interface equipped with MED-PC 
IV software (ENV-013; Med Associates, St. Albans, VT). The apparatus was 68 x 21 
x 21 cm and consisted of three distinct compartments: two 28-cm long side 
compartments (one colored black with a stainless steel rod floor and one colored 
white with a stainless steel mesh floor) separated by a 12-cm long central gray 
compartment with a smooth PVC floor.  Guillotine doors separated each side 
chamber from the central chamber and were manipulated in order to confine rats to 
one of the side compartments or to allow free access to all three compartments. 
Inside each side compartment, six photobeams were located 1.25 cm from the end 
wall and 5 cm apart. Inside the central gray compartment, there were three 
photobeams spaced 4.75 cm apart.   
 
Experimental Procedure 
Twelve separate groups of animals (n=8-11) were used in the current study, 
making up a 3 x 4 (lobeline dose x methamphetamine dose) experimental design.  
On Day 1 (preconditioning test), animals were placed individually in the apparatus 
with both guillotine doors open to allow access to the entire apparatus for 15 min to 
determine the initial preference.  On Days 2-9 (conditioning sessions), animals were 
confined to each side of the apparatus on alternating days.  On drug conditioning 
days, animals were pretreated with saline or lobeline (1 or 3 mg/kg, SC) and were 
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placed back into their home cage for 15 min. Animals were then injected with saline 
or methamphetamine (0.5, 1 or 3 mg/kg, IP) and placed immediately in one of the 
side compartments (white or black; counterbalanced within treatment group 
regardless of initial preference) for 30 min.  Locomotor activity was recorded as the 
number of beam breaks on the last drug conditioning trial.  On the alternating days, 
animals were treated similarly except that both injections were saline and the 
animals were placed into the opposite side compartment.  On Day 10 
(postconditioning test), preference was assessed by placing the animal in the center 
grey compartment with free access to all compartments for 15 min.  The amount of 
time spent in each compartment was recorded and CPP was defined as a 
significant increase in time spent in the drug-paired compartment relative to the 
saline-paired compartment.   
 
Data Analysis 
Locomotor activity was assessed by analyzing the number of horizontal 
beam breaks during the last drug-conditioning session using a one-way ANOVA 
across treatment groups.  Posthoc analyses were conducted using unpaired t-tests 
(one-tailed) with correction for family-wise error to determine significant between 
group differences.  Significance level for all analyses was set at p<0.05.  Preference 
data were analyzed as time (sec) spent in the saline versus drug-paired 
compartments during the postconditioning test session using a 12 x 2 (treatment 
groups x compartment) mixed factor analysis of variance (ANOVA), with treatment 
groups as a between-subject factor and compartment as a within-subject, repeated 
measure factor.  Posthoc analyses were conducted using paired t-tests (one-tailed) 
with correction for family-wise error to assess differences in time spent in saline 
versus drug-paired compartments within each group.   
 
Results 
Locomotor Activity 
The overall analysis of locomotor activity during the last drug conditioning 
session revealed a significant main effect of treatment group (F(11,98)=3.185; 
p<0.001).  Figure 2.1 illustrates that all methamphetamine (0.5, 1.5 and 3 mg/kg) 
conditioning groups showed a significant increase in locomotor activity compared to 
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saline control (panel A), while no difference was observed between the saline 
control and either lobeline (1 and 3 mg/kg) alone groups (panel B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  Locomotor Activity During the 4th Drug Conditioning Session  
for Control Groups.  Mean (± SEM) horizontal beam breaks in the drug-paired 
compartment during the last drug conditioning session (Trial 4) following 
methamphetamine (0, 0.5, 1 or 3 mg/kg) alone (Panel A) or lobeline (0, 1 or 3 
mg/kg) alone (Panel B).  Asterisk (*) indicates a significant difference from SAL-
SAL group; p<0.05. 
 
Figure 2.2 illustrates that lobeline (1 and 3 mg/kg) pretreatment did not alter 
locomotor activity following the lower methamphetamine doses (0.5 mg/kg; panel A 
or 1.5 mg/kg; panel B) on the last conditioning session.  In addition, the lower dose 
of lobeline (1 mg/kg) did not significantly alter the effect of 3 mg/kg of 
methamphetamine (Figure 2.2, panel C).  However, 3 mg/kg of lobeline significantly 
attenuated locomotor activity following the highest dose of methamphetamine (3 
mg/kg).   
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Figure 2.2  Locomotor Activity During the 4th Drug Conditioning Session  
For Lobeline-Methamphetamine Groups.  Mean (± SEM) beam breaks in the 
drug-paired compartment during the last drug conditioning session (Trial 4) 
following pretreatment with lobeline (0, 1 or 3 mg/kg) prior to methamphetamine (0, 
0.5, 1 or 3 mg/kg).  The dashed line represents the number of beam breaks in the 
SAL-SAL group. Panel A: Lobeline (0, 1 or 3 mg/kg) pretreatment combined with 
methamphetamine (0.5 mg/kg).  Panel B: Lobeline (0, 1 or 3 mg/kg) pretreatment 
combined with methamphetamine (1.5 mg/kg).  Panel C: Lobeline (0, 1 or 3 mg/kg) 
pretreatment combine with methamphetamine (3 mg/kg).  Asterisk (*) indicates a 
significant difference from SAL-SAL group, which is represented by the dashed line; 
p<0.05.  Hatch (#) indicates a significant difference from SAL-METH 3; p<0.05.  
 
Acquisition of Conditioned Place Preference 
The overall analysis of time spent in each compartment during the 
postconditioning test revealed significant main effects of treatment group 
(F(11,98)=8.06; p<0.01) and compartment (saline or drug-paired; F(1,98)=70.92; 
p<0.01).  In addition, ANOVA indicated that there was a significant interaction of 
compartment (saline or drug-paired) x treatment group (F(11,98)=3.71; p<0.01). 
Significant CPP was observed with each methamphetamine conditioning dose (0.5, 
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1.5 and 3 mg/kg; Fig 2.3A), while lobeline alone did not alter preference significantly 
(Fig 2.3B).  In addition, control rats conditioned with saline alone did not show a 
preference for either compartment during the postconditioning test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3  Acquisition of CPP for Control Groups.  Mean (± SEM) amount of 
time rats spent in the saline- and drug-paired compartments during the 15 min 
postconditioning test following methamphetamine (0, 0.5, 1 or 3 mg/kg; Panel A) or 
lobeline (0, 1 or 3 mg/kg; Panel B) alone.  Asterisk (*) indicates a significant within-
subject difference in time spent in the saline versus drug paired compartment; 
p<0.05.  
During conditioning with the lowest dose of methamphetamine (0.5 mg/kg), 
pretreatment with either dose of lobeline (1 or 3 mg/kg) blocked the acquisition of 
methamphetamine-induced CPP (Figure 2.4 A).  However, during conditioning with 
the higher methamphetamine doses (1.5 or 3 mg/kg), pretreatment with either dose 
of lobeline (1 or 3 mg/kg) during conditioning had no significant effect on the 
acquisition of methamphetamine-induced CPP (Figure 2.4B and 2.4C), as rats 
spent more time in the previously drug-paired compartment during the 
postconditioning test. 
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Figure 2.4  Acquisition of CPP in Lobeline-Methamphetamine Groups.  Mean 
(± SEM) amount of time spent in the saline- and drug-paired compartments during 
the 15-min postconditioning test for the groups pretreated with lobeline (0, 1 or 3 
mg/kg) prior to methamphetamine (0, 0.5, 1 or 3 mg/kg) during the conditioning 
phase.  Panel A: lobeline (0, 1 or 3 mg/kg) pretreatment combined with 
methamphetamine (0.5 mg/kg).  Panel B: Lobeline (0, 1 or 3 mg/kg) pretreatment 
combined with methamphetamine (1.5 mg/kg).  Panel C: Lobeline (0, 1 or 3 mg/kg) 
pretreatment combined with methamphetamine (3 mg/kg).  Asterisk (*) indicates a 
significant within-subject difference in time spent in the saline versus drug paired 
compartment; p<0.05.  
 
Summary of Experiment 1 
The aim of the current experiment was to examine the effect of lobeline on 
methamphetamine-induce locomotor hyperactivity and acquisition of CPP.  During 
the last drug conditioning session, rats were confined to one end compartment and 
horizontal beam breaks were recorded for the 30 min session.  Methamphetamine 
(0.5, 1.5 and 3 mg/kg) dose dependently induced hyperactivity during the last 
conditioning session compared to the saline control group, while lobeline (1 or 3 
mg/kg) alone did not alter locomotor activity during this session.  Previous research 
suggests that acute lobeline (3 mg/kg) induces non-specific hypoactivity in rats 
(Harrod et al., 2001; Miller et al., 2001).  Lobeline (3 mg/kg) did significantly 
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attenuate locomotor activity during the first conditioning session in the current study 
(data not shown).  However, tolerance to the hypoactivity was evident within four 
administrations, as no hypoactivity was evident on the last conditioning session.  
The lower dose of lobeline (1.0 mg/kg) did not block methamphetamine (0.5, 1.5 or 
3.0)-induced hyperactivity.  Interestingly, the higher dose of lobeline (3.0 mg/kg) 
attenuated locomotor hyperactivity only in combination with the highest 
methamphetamine (3.0 mg/kg) dose administered.  When the methamphetamine 
dose is increased from 1.5 to 3 mg/kg, additional pharmacological consequences 
may be induced that contribute to the increase in methamphetamine-induced 
hyperactivity.  Lobeline may be interfering with these additional pharmacological 
mechanisms, resulting in a decrease in methamphetamine-induced locomotor 
activity. 
All rats receiving methamphetamine during the conditioning phase acquired 
CPP. Importantly, neither dose of lobeline (1 or 3 mg/kg) induced CPP or place 
aversion, which is congruent with previous findings (Fudala & Iwamoto, 1986).  As 
hypothesized, lobeline (1 and 3 mg/kg) administration prior to methamphetamine 
(0.5 mg/kg) during the conditioning phase blocked the acquisition of CPP.  
However, the lobeline-induced blockade was surmounted when rats were 
conditioned with higher doses of methamphetamine (1.5 and 3.0 mg/kg).  
Interestingly, previous research from our laboratory has indicated that the ability of 
lobeline to decrease methamphetamine self-administration is not surmounted by 
increasing the unit dose of methamphetamine (Harrod et al., 2001). This 
discrepancy in results obtained from self-administration and CPP paradigms is not 
unique as previous research has demonstrated that pharmacological manipulations 
can differentially affect these paradigms (Bardo & Bevins, 2000).  The current 
results demonstrate that lobeline (1 and 3 mg/kg) can decrease the acquisition of 
CPP induced by a low dose of methamphetamine (0.5 mg/kg).  In addition, the 
lobeline (3 mg/kg)-induced attenuation of methamphetamine (3 mg/kg)-induced 
hyperactivity was not correlated with a decrease in the rewarding properties of 
methamphetamine, demonstrating that these two behavioral effects are dissociable.   
 
 
Copyright © Nichole Marie Neugebauer 2008
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CHAPTER THREE 
Experiment 2 
 
Lobeline Attenuates the Expression of Methamphetamine-Induced 
Conditioned Place Preference 
 
 In order to determine if lobeline attenuates the expression of an established 
methamphetamine CPP, lobeline was administered prior to postconditioning tests.  
As discussed in the introduction, the neurochemical mechanisms involved in the 
acquisition of methamphetamine CPP are dissociable from those involved in the 
expression of methamphetamine CPP.  This is clinically relevant because 
methamphetamine-induced cellular adaptations and learned associations are 
generally formed prior to an individual seeking treatment for dependence.  The 
expression of CPP in rodents is thought to model context-conditioned reward in 
humans.  Although no parallel experimental paradigm has been established in 
humans, it is well recognized that exposure to contextual cues that have been 
associated previously with drug effects often elicit drug craving.  It has been 
previously reported that lobeline does not specifically attenuate methamphetamine-
induced reinstatement of lever responding in rats following extinction of 
methamphetamine self-administration (Harrod et al., 2003).  As such, it was 
hypothesized that lobeline would not specifically inhibit the expression of 
methamphetamine-induced CPP. 
 
Methods 
Subjects 
One hundred and four male Sprague-Dawley rats (n=10-12/group; 225-250 
g; Harlan Industries, Indianapolis, IN) were used in the current study.  These rats 
were treated identically to those described in experiment 1.  
 
Drugs 
Same as described in Experiment 1. 
 
Apparatus 
Same as described in Experiment 1. 
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Experimental Procedure 
Nine separate groups of animals were assigned randomly to one of nine 
different treatment groups, making up a 3 x 3 factorial design (Table 1).   
 
Table 3.1  Experimental groups for Experiment 2. 
Drug Conditioning Postconditioning Test n
SAL SAL 10
SAL LOB 1 mg/kg 10
SAL LOB 3 mg/kg 12
METH 0.5 mg/kg SAL 12
METH 0.5 mg/kg LOB 1 mg/kg 12
METH 0.5 mg/kg LOB 3 mg/kg 12
METH 1.5 mg/kg SAL 12
METH 1.5 mg/kg LOB 1 mg/kg 12
METH 1.5 mg/kg LOB 3 mg/kg 12  
 
On Day 1 (preconditioning test), animals were placed in the apparatus with 
both guillotine doors open to allow access to the entire apparatus during which their 
initial place preference during a 15-min session was determined.  On Days 2-9 
(conditioning phase), animals were confined to one of the end compartments and 
underwent saline or drug conditioning trials on alternating days.  On drug 
conditioning trials, animals were administered saline or methamphetamine (0.5 or 
1.5 mg/kg, IP) and immediately placed in one of the end compartments in a 
counterbalanced manner (white or black; drug paired compartment) for 30 min. 
These doses of methamphetamine were chosen based on previously published 
results and based on preliminary experiments from our laboratory indicating that 0.5 
mg/kg of methamphetamine is the minimal dose that will result in reliable 
conditioned place preference (Kuo et al., 2007).  On alternate days, animals were 
injected with saline (IP) and placed in the opposite end chamber (saline paired 
compartment). On Days 10-11 (postconditioning tests), saline or lobeline (1 or 3 
mg/kg, SC) was administered in a counter balanced manner and 15 min later 
methamphetamine-induced conditioned place preference was assessed by placing 
the animal in the grey (center) compartment with free access to all compartments 
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for 15 min.  These postconditioning tests are referred to as the 1st saline and 1st 
lobeline post-tests.  On Days 12-15, each rat was administered saline or their 
respective dose of lobeline for 4 consecutive days and tested in an identical 
procedure described for the previous postconditioning test in order to assess the 
effects of repeated lobeline.  Days 12-15 are referred to as the 2nd to 5th lobeline 
post-tests.  On Day 16, all animals received saline prior to a postconditioning test in 
order to assess the persistence of the methamphetamine-induced CPP.   Day 16 is 
referred to as the final saline post-test. 
 
Data Analysis 
 All data are expressed as group means ± SEM.  Initially, horizontal beam 
breaks in each of the compartments were recorded during each postconditioning 
test and a rate of locomotor activity was calculated using the following equation: 
horizontal beam breaks / time spent in compartment.  These data were analyzed 
using a mixed factor ANOVA with group as a between-subject variable and 
compartment and postconditioning test day as within-subject variables. This 
analysis indicated no differences in the rate of locomotor activity between the two 
end compartments so the beam breaks were collapsed in all subsequent analyses.  
Locomotor activity data are expressed as the total number of horizontal beam 
breaks in all 3 compartments during each of the postconditioning tests as and were 
analyzed using a mixed factor ANOVA, with group as a between-subject variable 
and postconditioning test day as a within-subject variable.  Post-hoc analyses were 
conducted using paired and unpaired t-tests (one-tailed) with correction for family-
wise error to determine significant group differences.  CPP data were analyzed as 
time (sec) spent in the saline versus methamphetamine-paired compartments 
during the postconditioning-test using an overall 3-way mixed factor ANOVA, with 
group as a between-subject variable and compartment and postconditioning test 
day as within-subject variables.  Subsequent 3-way ANOVAs were conducted for 
each conditioning group.  Post-hoc analyses were conducted using paired t-tests 
(one-tailed) with correction for family-wise error to determine significant decreases 
in time spent in the saline versus drug-paired compartments within each 
conditioning group.  In order to assess whether the non-specific hypoactivity 
typically induced by lobeline confounds the expression of CPP, correlational 
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analyses were conducted.  For these analyses, a difference score was calculated 
for CPP using the following equation: time spent in drug – time spent in saline.  
Separate Pearson’s correlations were conducted using the CPP difference score 
and total horizontal beam breaks on each of the postconditioning test sessions.  
Significance level (alpha) for all analyses was set at p<0.05.   
 
Results 
Locomotor Activity During Postconditioning Tests 
The overall 2-way ANOVA of locomotor activity across postconditioning tests 
indicated significant main effects of treatment group (F(8,92)=3.69; p<0.01) and 
postconditioning test (F(3,24)=37.18; p<0.01).  An interaction of treatment group x 
postconditioning test was also revealed (F(24,276)=8.07; p<0.01).  Three separate 
groups of animals were administered saline during the conditioning phase of the 
experiment and underwent repeated postconditioning test sessions (Figure 3.1).  
Within the group that was repeatedly challenged with saline during these 
postconditioning tests, a decrease in activity was observed by the 5th repeated 
postconditioning test (p<0.05).  Interestingly, no decrease was observed in rats 
repeatedly challenged with the lower dose of lobeline (1 mg/kg), indicating an effect 
indicative of habituation.  Administration of the higher dose of lobeline (3 mg/kg) 
resulted in acute and persistent suppression of locomotor activity (p<0.05).  
However, some tolerance to the suppressant effect was observed between the 1st 
and 5th lobeline administration (p<0.05).  No significant decrease was observed 
between the 1st and final saline challenge sessions, indicating no enduring 
suppressant effect of lobeline.   
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Figure 3.1  Locomotor Activity During Postconditioning Tests in Rats  
that Received Saline During the Conditioning Phase.  Mean (± SEM) horizontal 
beam breaks in the CPP apparatus following lobeline (0, 1 or 3 mg/kg) pretreatment 
during the 15-min postconditioning test session.  All rats received saline during the 
conditioning phase.  Asterisk (*) indicates a significant difference between bars 
(p<0.05). 
 
Three separate groups of animals were administered a low dose of 
methamphetamine (0.5 mg/kg) during the conditioning phase of the experiment and 
underwent repeated postconditioning test sessions (Figure 3.2). Rats repeatedly 
challenged with saline showed no differences across postconditioning test sessions 
(p<0.05).  However, a significant decrease was observed following repeated testing 
with the lower dose of lobeline (1 mg/kg). The higher dose of lobeline (3 mg/kg) 
resulted in acute and persistent suppression of locomotor activity (p<0.05).  
However, some tolerance to this suppressant effect was observed between the 1st 
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and 5th lobeline administration (p<0.05).  A significant decrease was also observed 
between the 1st and final saline challenge sessions. 
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Figure 3.2  Locomotor Activity During Postconditioning Tests in Rats that 
Received Methamphetamine (0.5 mg/kg) During the Conditioning Phase.  
Mean (± SEM) horizontal beam breaks in the CPP apparatus following lobeline (0, 1 
or 3 mg/kg) pretreatment during the 15-min postconditioning test session.  All rats 
received methamphetamine (0.5 mg/kg) during the conditioning phase.  Asterisk (*) 
indicates a significant difference between bars (p<0.05). 
 
Three separate groups of animals were administered a high dose of 
methamphetamine (1.5 mg/kg) during the conditioning phase of the experiment and 
underwent repeated postconditioning test sessions (Figure 3.3).  Rats repeatedly 
challenged with saline across postconditioning tests showed a significant decrease 
by the final saline postconditioning test, suggestive of habituation to the test 
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chamber (Figure 3.6; p<0.05).  A decrease was also observed between the 1st 
saline and last saline postconditioning test sessions in rats repeatedly challenged 
with the lower dose of lobeline (1 mg/kg).  Administration of the higher dose of 
lobeline (3 mg/kg) resulted in acute and persistent suppression of locomotor activity 
(p<0.05).  However, some tolerance to this suppressant effect was observed 
between the 1st and 5th lobeline administration (p<0.05).  A significant decrease was 
also observed between the 1st and final saline challenge sessions. 
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Figure 3.3  Locomotor Activity During Postconditioning Tests in Rats that 
Received Methamphetamine (1.5 mg/kg) During the Conditioning Phase.  
Mean (± SEM) horizontal beam breaks in the CPP apparatus following lobeline (0, 1 
or 3 mg/kg) pretreatment during the 15-min postconditioning test session.  All rats 
received methamphetamine (1.5 mg/kg) during the conditioning phase.  Asterisk (*) 
indicates a significant difference between bars (p<0.05). 
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Expression of Conditioned Place Preference 
 The overall analysis of time spent in the saline versus drug paired 
compartments across 7 consecutive postconditioning test days indicated significant 
main effects of test day (F(3,276)=3.07; p<0.05) and compartment (F(1,92)=25.32; 
p<0.01).  In addition, a significant compartment x group interaction (F(8,276)=2.01; 
p<0.05) was revealed.  Separate 3-way ANOVAs were conducted for each of the 3 
conditioning groups (0, 0.5 and 1.5 mg/kg).  There were no significant differences 
found in the saline conditioned groups (Figure 3.4 Panels A-D).   
     1st SAL Post-Test
SAL LOB 1 LOB 3
0
100
200
300
400
500
DRUG
SAL
A
T
im
e
  
S
p
e
n
t 
in
 C
o
m
p
a
rt
m
e
n
t 
 (
s
e
c
)
     1st LOB Post-Test
SAL LOB 1 LOB 3
B      5th LOB Post-Test
SAL LOB 1 LOB 3
C        Final SAL Post-Test
SAL LOB 1 LOB 3
D
Saline Conditioned  Groups
Postconditioning Test Pretreatment
 
Figure 3.4  Expression of CPP in Rats that Received Saline During the  
Conditioning Phase.  Mean (± SEM) amount of time spent in the saline- and drug-
paired compartments in the saline conditioned control group pretreated with lobeline 
(0, 1 or 3 mg/kg) 15 min prior to 15-min postconditioning test sessions.  Panel A-D: 
No group exhibited CPP during any of the postconditioning test sessions.   
 
However, in the methamphetamine (0.5 mg/kg) conditioned groups (Figure 
3.5) the analysis revealed a main effect of compartment (F(1,33)=21.33; p<0.01).  
Planned comparisons that revealed all groups conditioned with methamphetamine 
(0.5 mg/kg) spent significantly more time in the drug paired compartment on the 1st 
saline and final saline postconditioning tests, indicating a persistent 
methamphetamine-induced CPP across the repeated test days.  The lower dose of 
lobeline (1 mg/kg) did not attenuate this response on the 1st lobeline 
postconditioning test.  Interestingly, repeated administration of this dose did 
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attenuate the expression of CPP on the 5th lobeline postconditioning test (p<0.05).  
The higher dose of lobeline (3 mg/kg) attenuated the expression of CPP on both the 
1st and 5th lobeline postconditioning tests (p<0.05).   
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Figure 3.5   Expression of CPP in Rats that Received Methamphetamine  
(0.5 mg/kg) During the Conditioning Phase.  Mean (± SEM) amount of time spent 
in the saline- and drug-paired compartments in treatment groups conditioned with 
methamphetamine (0.5 mg/kg) and pretreated with lobeline (0, 1 or 3 mg/kg) 15 min 
prior to 15-min postconditioning test sessions. Panel A: All treatment groups 
showed significant acquisition of methamphetamine CPP.  Panel B: Acute lobeline 
(3 mg/kg) pretreatment blocked the expression of methamphetamine (0.5 mg/kg)-
induced CPP.  Panel C: Repeated lobeline (1 or 3 mg/kg) pretreatment blocked the 
expression of methamphetamine (0.5 mg/kg)-induced CPP.  Panel D: All treatment 
groups showed persistent expression of methamphetamine CPP on the final saline 
challenge day.  Asterisk (*) indicates a significant difference in time spent in the 
saline versus drug paired compartment; p<0.05.  
 
In the methamphetamine (1.5 mg/kg) conditioned groups (Figure 3.6), the 
analysis revealed a main effect of compartment (F(1,32)=18.20; p<0.01), as well as 
an interaction of compartment x test day (F(3,96)=2.80; p<0.05).  Planned 
comparisons revealed that rats conditioned with methamphetamine (1.5 mg/kg) and 
given a saline injection on the 1st and final saline postconditioning tests showed 
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significant CPP, indicating a persistent methamphetamine-induced CPP across test 
days.  The lower dose of lobeline (1 mg/kg) did not attenuate this response on the 
1st lobeline postconditioning test, but repeated administration of this dose did 
attenuate the expression of CPP on the 5th postconditioning test (p<0.05).  
However, the higher dose of lobeline (3 mg/kg) attenuated the expression of CPP 
on both the 1st and 5th lobeline postconditioning tests (p<0.05).  In addition, the 
lobeline (1 and 3 mg/kg) pretreatment groups did not show significant conditioned 
place preference on the final saline postconditioning test.  
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Figure 3.6  Expression of CPP in Rats that Received Methamphetamine  
(1.5 mg/kg) During the Conditioning Phase.  Mean (± SEM) amount of time spent 
in the saline- and drug-paired compartments in treatment groups conditioned with 
methamphetamine (1.5 mg/kg) and pretreated with lobeline (0, 1 or 3 mg/kg) 15 min 
prior to 15-min postconditioning test sessions. Panel A: All treatment groups 
showed significant acquisition of methamphetamine CPP.  Panel B: Acute lobeline 
(3 mg/kg) pretreatment blocked the expression of methamphetamine (0.5 mg/kg)-
induced CPP.  Panel C: Repeated lobeline (1 or 3 mg/kg) pretreatment blocked the 
expression of methamphetamine (0.5 mg/kg)-induced CPP.  Panel D: Repeated 
lobeline (1 or 3 mg/kg) pretreatment resulted in extinction of CPP on the final saline 
postconditioning test.  Asterisk (*) indicates a significant difference in time spent in 
the saline versus drug paired compartment; p<0.05.  
   No significant correlation was found between locomotor activity and 
expression of CPP when all conditioning groups were included on the 1st SAL (r = 
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.15, n=101, n.s.), 1st LOB (r = .09, n=101, n.s.), 5th LOB (r = .19, n=101, n.s.) or 
Final SAL (r = .04, n=101, n.s.) postconditioning tests.  Correlations conducted on 
each of the experimental groups at each postconditioning test day indicated no 
correlation existed between locomotor activity and expression of CPP. 
 
Summary of Experiment 2 
 The aim of the current experiment was extend the findings presented in 
Experiment 1 by assessing the effects of lobeline on expression of 
methamphetamine-induced CPP.  During the repeated postconditioning sessions, 
rats were administered saline or lobeline (1 or 3 mg/kg) 15 min prior to being placed 
in the CPP apparatus where they had access to all 3 compartments.  Horizontal 
beam breaks were recorded for the 15 min test session.  No differences between 
conditioning groups were observed on the first saline postconditioning test, 
indicating no conditioned hyperactivity in the methamphetamine conditioned groups.  
Regardless of conditioning group, significant decreases in locomotor activity were 
observed across the postconditioning sessions in rats that received saline or 
lobeline (1 mg/kg).  However, these differences were small and likely due to 
habituation to the testing apparatus.  Interestingly, lobeline (3 mg/kg) induced 
hypoactivity across all conditioning groups.  While tolerance to this hypoactivity was 
evident following 5 repeated administrations, significant hypoactivity compared to 
saline was still observed.  The expression of CPP was not correlated with locomotor 
activity, indicating that the expression of CPP is not likely masked by locomotor 
suppression.  
In rats conditioned with the lower dose of methamphetamine (0.5 mg/kg), all 
groups spent significantly more time in the previously drug versus saline-paired 
compartment on the first saline postconditioning test, indicating significant 
acquisition of CPP.  Moreover, the methamphetamine (0.5 mg/kg) conditioned 
groups, regardless of postconditioning test pretreatment, maintained significant 
CPP across postconditioning tests, demonstrating the persistence of CPP across 
the experimental regimen.  Acute administration of the lower dose of lobeline (1 
mg/kg) did not attenuate the expression of CPP (1st LOB Post-Test).  However, by 
the 5th lobeline administration, a significant attenuation was observed, indicating 
differences in acute and repeated effects of this lower dose of lobeline.  In addition, 
 37 
acute and repeated administration of the higher dose of lobeline (3 mg/kg) resulted 
in a persistent blockade in expression of CPP. 
Following conditioning with the higher dose of methamphetamine (1.5 
mg/kg), all groups showed significant acquisition of CPP.  In contrast to the 
methamphetamine (0.5 mg/kg) conditioned groups, the methamphetamine (1.5 
mg/kg) conditioned groups showed less persistent CPP.   In rats that received 
saline across all postconditioning tests, significant expression of CPP on the 5th 
lobeline postconditioning test was not observed.  It is not clear why significant CPP 
was not observed on this day, but was again evident on the final saline 
postconditioning test.  In addition, neither lobeline (1 or 3 mg/kg) pretreatment group 
demonstrated significant CPP on the final saline postconditioning test.  Similar to 
the effects observed in the methamphetamine (0.5 mg/kg)-conditioned group, acute 
administration of the lower dose of lobeline (1 mg/kg) had effect no on the 
expression of CPP, but attenuation was evident following repeated administration.  
In addition, this group did not show persistent CPP on the final saline 
postconditioning test.  Acute and repeated administration of the higher dose of 
lobeline (3 mg/kg) blocked expression of CPP and suppressed locomotor activity on 
the 1st and 5th lobeline administration.  However, this group did not show significant 
CPP on the final saline postconditioning test.  Contrary to the hypothesis, these 
results demonstrate that repeated administration of lobeline decreases expression 
of methamphetamine-induced CPP.  It is not clear why the expression of CPP was 
persistent across repeated postconditioning tests when a low dose of 
methamphetamine (0.5 mg/kg) was, but not when a high dose (1.5 mg/kg) was 
used.  It is unlikely that the absence of CPP in the methamphetamine (1.5 mg/kg) 
conditioned groups that received repeated lobeline is due to non-specific extinction 
of CPP as groups pretreated with saline during the repeated postconditioning-tests 
continued to display significant CPP on the final test day.  In addition, previous work 
has shown that methamphetamine CPP is resistant to extinction when rats are 
given repeated postconditioning tests for 10 consecutive days (Bahi, Kusnecov, & 
Dreyer, 2008).   
 
 
Copyright © Nichole Marie Neugebauer 2008
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CHAPTER FOUR 
Experiment 3 
 
Lobeline Alters Methamphetamine-Induced Changes in the Nucleus 
Accumbens Shell 
 
The nucleus accumbens shell is a neuroanatomical area that has been 
implicated in playing a vital role in mediating the reinforcing effects of 
psychostimulants.  Dopaminergic mechanisms in this brain region have been shown 
to be particularly important in the circuitry underlying drug-taking behaviors.  Since 
lobeline has been shown to attenuate behaviors associated with the reinforcing and 
rewarding aspects of methamphetamine, it is of interest to assess the effects of 
lobeline on extracellular dopamine in this brain region.  In addition, the mechanism 
by which lobeline disrupts methamphetamine-induced alterations in dopamine 
release has been assessed solely at the in vitro level, so determining if this 
neurochemical effect is also observed in vivo using microdialysis in an awake and 
behaving animal is warranted.  Additionally, extracellular levels of DOPAC were 
assessed to determine if systemic lobeline administration results in an increased 
level of extracellular DOPAC, as lobeline is thought to increase the amount of 
cytosolic dopamine available for metabolism (Dwoskin & Crooks, 2002).  It was 
hypothesized that lobeline would attenuate methamphetamine-induced alterations 
in extracellular dopamine and DOPAC in the nucleus accumbens shell. 
 
Methods 
Subjects 
Male Sprague-Dawley rats (N=32; 225-250 g) were obtained from Harlan 
Industries (Indianapolis, IN) and housed one per cage.  In all other respects, rats 
were cared for as described in Experiment 1. 
 
Drugs and Chemicals  
Ketamine (80 mg/kg, IP) and diazepam (5 mg/kg, IP) were be used as 
anesthetics during surgical procedures.  All other drugs were the same as described 
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in Experiment 1.  All reagents for the aCSF, HPLC mobile phase were obtained 
from Sigma (St. Louis, MO).  
 
Surgery  
Animals were anesthetized and implanted with guide cannula (secured with 
dental acrylic) aimed at the nucleus accumbens using the following coordinates 
relative to bregma: AP +1.6 mm, L +0.8 mm, and D/V -5.8 mm (Paxinos & Watson, 
1986). Guide cannula (20 gauge; MD-2251) and probes (2mm; MD-2200) were 
obtained from BAS (Indianapolis, Indiana). 
 
In Vivo Microdialysis 
Microdialysis experiments were conducted using a swivel system (BAS) 
attached to the side of a Plexiglass chamber (25 x 44 x 38 cm), which contained 
pine chip bedding.  Rats were assigned randomly to one of 6 different treatment 
groups making up a 3 x 2 factorial design (Table 2).  The day before the 
microdialysis session, each animal was fitted with a plastic collar.  The next day, 
rats were weighed and habituated to the plexiglass chamber for at least 30 min.  
The microdialysis probe, which was connected to a microsyringe pump (KD 
Scientific, Model KDS250) via PE10 tubing that was slowing perfusing artificial 
cerebral spinal fluid (aCSF; consisting of: 145 mM sodium chloride, 2.7mM 
potassium chloride, 1 mM magnesium chloride, 1.2 calcium chloride, and 2.0 mM 
sodium phosphate) through the probe at a flow rate of 1.2 μl/min, was inserted into 
the guide cannula and the animal was connected to the swivel system by attaching 
a leash to the collar.  The rats were then habituated to the Plexiglas chamber and 
probe insertion for at least 3.5 hr prior to collection of the baseline samples.  
Baseline samples were collected into polyethylene microfuge tubes containing 5 μl 
of 0.1 N perchloric acid every 20 min for 60 min.  After collection of 3 baseline 
samples, each rat was administered either saline or lobeline (1 or 3 mg/kg, SC) and 
5 min later injected with saline or methamphetamine (0.5 mg/kg, IP).   
 
 
 
 40 
Table 4.1  Experimental groups in Experiment 2. 
 
 
 
 
 
 
 
 
Dialysis samples were collected every 20 min for an additional 3 hr after the 
second injection. Samples were frozen immediately on dry ice and stored at  -70˚ C 
for later analysis.  Following the microdialysis experiment, the brains were removed 
and flash frozen in Chromasolv® (Sigma).  Brains were sectioned into 40 μm 
coronal slices, mounted onto slides and stained with cresyl violet.  Microdialysis 
probe placement in the nucleus accumbens was confirmed as indicated by Paxinos 
and Watson (1986) and only data from rats with confirmed probe placement were 
included.   
 
Analysis of Extracellular Dopamine and DOPAC using HPLC-EC 
Samples were thawed and analyzed immediately for dopamine and DOPAC 
(3,4-dihydroxy-phenylacetic acid ) using HPLC-EC (ESA Chelmsford, MA, USA) as 
previously described (Rahman et al., 2003).  The system consisted of a computer 
running EZ-Chrome Elite software, a solvent delivery system (ESA pump 582), a 3 
μm, C18 column with guard column, a Coulochem III 5200A electrochemical 
detector and manual injector equipped with an ESA 5011 analytical cell and 5020 
guard cell.  The guard cell was set at 225 mV, the reference electrode on at –
150mV and the working electrode was 225mV.  The gain was set to 1μ A and 
changed to 10 nA at 4.5 min in order to assess both DOPAC and DA in the same 
sample. The mobile phase consisted of: 75 mM NaH2PO4, 1.7 nM 1-octanesulfonic 
acid, 25 μM EDTA, 100 μl/l triethylamine and 10 % acetonitrile; pH 3.0 adjusted with 
phosphoric acid, and pumped through the system at a rate of 0.65 ml/min.  Samples 
were loaded into a 20 μl sample loop and manually injected onto an analytical 
column (BetaBasic-18 column, 150 mm x 3mm; Keystone Scientific, PA, USA).  
Pretreatment (Inj 1) Treatment (Inj 2) n
SAL SAL 4
SAL METH 0.5 mg/kg 6
LOB 1 mg/kg SAL 6
LOB 1 mg/kg METH 0.5 mg/kg 7
LOB 3 mg/kg SAL 6
LOB 3 mg/kg METH 0.5 mg/kg 7
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External standards were used to determine the actual concentrations of dopamine 
and DOPAC in each sample.   
 
Data Analysis 
Data were recorded as peak height for DOPAC and dopamine for each 
sample collected.  These data were then expressed as a percent of baseline 
(average of the 1st three samples) and analyzed with SPSS (Chicago, IL) software 
using 2-way repeated measures ANOVA (Treatment Group x Time). In addition, 
area under the curve was calculated for each experimental group and analyzed with 
a one way ANOVA across treatment group. Post-hoc analyses for between-subject 
effects were conducted using unpaired t- tests and paired t-tests with correction for 
family wise error were used to compare within-subject data points. 
 
Results 
Histology 
      
     A/P: 1.6   A/P: 1.7          A/P: 2.2 
Figure 4.1  Placement of Microdialysis Probes. Each vertical bar represents an 
animal that was included in the analysis of the microdialysis experiment.  
 
Analysis of Extracellular Dopamine in the Nucleus Accumbens Shell 
 The mean (± SEM) basal dopamine concentration was 0.60 ± 0.05 nM and 
the basal DOPAC concentration was 471 ± 24 nM.  An overall analysis of dopamine 
levels using a 5 (treatment group) x 12 (time) mixed factor ANOVA with treatment 
group as a between subject variable and time as a within subject variable indicated 
significant main effects of group (F(4,27)=4.54; p<0.01) and time (F(11,297)=24.74; 
p<0.01).  This analysis also indicated a significant group x time interaction 
(F(44,297)=4.27; p<0.01).  Posthoc analysis indicated that the groups receiving 
methamphetamine (0.5 mg/kg) showed a significant increase in dopamine levels 
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compared to baseline (Figure 4.2; p<0.05).  Analysis of the area under the curve for 
each group indicated a significant groups effect (F(4,27)=5.25;p<0.01).  Posthoc 
analysis indicated none of the methamphetamine treatment groups were 
significantly different from each other.  Interestingly, lobeline had no effect on the 
methamphetamine-induced increase in dopamine, nor did it have any effect when 
administered prior to saline.   
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Figure 4.2  Extracellular Dopamine Levels in the Nucleus Accumbens  
Shell.  Mean (± SEM) percent baseline of the dopamine peak height for each time 
point following administration of lobeline (LOB) and/or methamphetamine (METH).  
The arrow indicates time of treatment.  Symbols indicate differences from the 
respective group’s baseline.  The thick dashed line represents the baseline.  The 
insert is the calculated area under the curve for each group. 
 
Analysis of Extracellular DOPAC in the Nucleus Accumbens Shell 
An overall analysis of DOPAC levels using a 5 (treatment group) x 12 (time) mixed 
factor ANOVA, with treatment group as a between subject variable and time as a 
within subject variable, indicated significant main effects of group (F(4,27)=11.21; 
p<0.01) and time (F(11,297)=8.91; p<0.01).  This analysis also indicated a 
significant group x time interaction (F(44,297)=7.96; p<0.01).  Posthoc analysis 
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indicated that the groups receiving methamphetamine (0.5 mg/kg) showed a 
significant decrease in DOPAC levels compared to baseline (Figure 4.3; p<0.05).  
Furthermore, lobeline administration significantly enhanced this decrease in a dose-
dependent manner (p<0.05).  Analysis of the area under the curve for each group 
indicated a significant groups effect (F(4,27)=9.14; p<0.01).  Posthoc analysis 
indicated none of the methamphetamine treatment groups were significantly 
different from each other.  Interestingly, while lobeline enhanced the 
methamphetamine-induced decrease in DOPAC, it increased DOPAC levels dose-
dependently when administered alone (p<0.05).   
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Figure 4.3  Extracellular DOPAC Levels in the Nucleus Accumbens  
Shell.  Mean (± SEM) percent baseline of the DOPAC peak height for each time 
point following administration of lobeline (LOB) and/or methamphetamine (METH).  
The arrow indicates time of treatment.  Symbols indicate differences from the 
respective group’s baseline.  The thick dashed line represents the baseline.  The 
insert is the calculated area under the curve for each group. 
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Summary of Experiment 3 
Microdialysis was conducted in awake, freely moving rats with probe 
placements in the nucleus accumbens shell.  Methamphetamine administration 
increased extracellular levels of dopamine in this brain region to ~ 450% of 
baseline, while lobeline alone had no effect.  Contrary to our hypothesis, 
pretreatment with either dose of lobeline (1 or 3 mg/kg) did not significantly alter the 
methamphetamine-induced increase in dopamine.  However, a slight attenuation 
following the higher dose of lobeline (3 mg/kg) at 60 min was noted.  Interestingly, 
lobeline alone increased DOPAC (~20%) at both doses tested, indicating an 
increase in dopamine metabolism.  As expected, methamphetamine alone 
decreased DOPAC by ~30%, indicating a decrease in dopamine metabolism.  
Lobeline pretreatment dose dependently enhanced the methamphetamine-induced 
decrease, indicating synergistic inhibition of dopamine metabolism when lobeline 
was administered prior to methamphetamine.  Specifically, lobeline (1 and 3 mg/kg) 
pretreatment prior to methamphetamine induced a more pronounced decrease in 
DOPAC at 60 min than methamphetamine alone.  Furthermore, the higher dose of 
lobeline (3 mg/kg) combined with methamphetamine decreased extracellular 
DOPAC for a longer period of time than methamphetamine alone. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Nichole Marie Neugebauer 2008
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CHAPTER FIVE 
General Discussion 
 
The overall hypothesis of the current experiments was that lobeline would 
block the acquisition and expression of methamphetamine-induced CPP and that 
this behavioral effect would be associated with an inhibition of methamphetamine-
induced dopamine release in the reward-relevant nucleus accumbens shell.  
Previous behavioral research has indicated that lobeline is effective at attenuating 
self-administration in rats, a behavior that is acquired and maintained through 
operant conditioning.  In the current studies, the effects of lobeline on 
methamphetamine-induced behaviors that are learned through classical 
conditioning were assessed.  Through this type of learning, environmental cues that 
were previously predictive of drug reward come to elicit a conditioned response, 
which is thought to contribute significantly to context-dependent relapse in humans.        
Few studies have examined the effects of low doses of lobeline (≤ 1 mg/kg) 
following repeated administration.  This dose of lobeline does not result in the non-
specific suppression of activity as is observed following the higher doses.  For 
example, lobeline (1 mg/kg) does not acutely decrease response rates in the drug 
discrimination paradigm in animals trained to discriminate nicotine or 
methamphetamine nor does this dose decrease operant responding for 
methamphetamine or food reinforcement (Damaj, Patrick, Creasy, & Martin, 1997; 
Harrod et al., 2001; Miller et al., 2003).  However, this dose of lobeline is 
behaviorally activity as it produces a conditioned taste aversion to a salt solution 
and has been shown to decrease the progressive ratio breakpoint for intracranial 
self-stimulation in rats (Harrod, Dwoskin, & Bardo, 2004; Wellman et al., 2008).  
This latter study also suggests that lobeline is not reinforcing as drugs of abuse 
increase the progressive ratio breakpoint for intracranial self-stimulation in rats.  The 
current experiments are the first to demonstrate that lobeline (1.0 mg/kg) also 
attenuates methamphetamine-induced reward and future studies assessing the 
repeated effects of lower doses of lobeline are warranted. 
Following acute administration of lobeline (≥ 3 mg/kg), a non-specific 
decrease in activity is often observed.  Tolerance to these non-specific effects is 
generally evident within ~5-7 repeated administrations.  In addition to locomotor 
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hypoactivity, as was observed in the current studies, higher doses of lobeline 
acutely decrease response rates in drug discrimination and operant responding for 
food (Harrod et al., 2001; Miller et al., 2001).  Little is known about the 
mechanism(s) underlying the lobeline-induced decrease in activity.  Currently, there 
are no known pharmacological manipulations that will block this hypoactivity 
following lobeline (≥ 3 mg/kg), making it difficult to know with certainty that acute 
administration of these doses decreases methamphetamine reward specifically and 
is not simply disrupting ongoing behavior in a non-specific manner.   
Lobeline, which is a nicotinic receptor ligand, is known to reliably produce 
emesis or nausea in humans and this illness-inducing effect may explain the 
decrease in behavior observed in rats (Dwoskin & Crooks, 2002).  Interestingly, 
while nicotine also produces a non-specific decrease in behavior when administered 
acutely, the non-specific, non-selective, nicotinic receptor antagonist mecamylamine 
blocks nicotine-induced hypoactivity, while having no effect on lobeline-induced 
hypoactivity (Damaj et al., 1997).  This suggests that while acute nicotine and 
lobeline administration produce a similar non-specific decrease in behavior, they do 
so via different pharmacological mechanisms.   
Research has suggested that neuronal nicotinic receptors modulate 
amphetamine-induced behaviors.  Antagonism of nicotinic receptors with 
mecamylamine prior to repeated amphetamine administration attenuates 
amphetamine-induced locomotor sensitization; interestingly, after amphetamine 
sensitization is established, mecamylamine has no effect on amphetamine-induced 
hyperactivity (Schoffelmeer, De Vries, Wardeh, Van De Ven, & Vanderschuren, 
2002).  This study suggests neuronal nicotinic receptors modulate amphetamine-
induced neuronal alterations.  Since lobeline is known to act as a nicotinic receptor 
antagonist, it is possible that this mechanism contributes to the lobeline-induced 
disruption of methamphetamine reward.  It is unlikely that antagonism of nicotinic 
receptors alone is responsible for the disruption of methamphetamine-induced CPP 
in the current study, as mecamylamine administration does not affect acquisition of 
methamphetamine self-administration, nor does it disrupt fully acquired 
methamphetamine self-administration (unpublished results from our laboratory).  
Evidence suggests that nicotinic receptor activity may be an important mechanism 
for the persistence of the effect of lobeline on methamphetamine reward.  This 
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evidence is based on work showing that lobelane, an analog of lobeline, selectively 
and potently inhibits the vesicular monoamine transporter and the dopamine 
transporter more potently than lobeline (Miller et al., 2004).  However, lobelane 
interacts with the nicotinic receptors less potently than lobeline (Miller et al., 2004).  
Similar to lobeline, lobelane was shown to acutely decrease methamphetamine self-
administration (Neugebauer et al., 2007).  However, rapid tolerance developed to 
the lobelane-induced decrease in methamphetamine self-administration upon 
repeated administration, suggesting that nicotinic receptor binding may be 
necessary for the persistent decrease in methamphetamine self-administration 
observed following repeated lobeline.  Further understanding of the role that 
nicotinic receptors play in psychostimulant-induced behaviors is necessary to fully 
characterize the contribution this mechanism may have on the persistent nature of 
lobeline-induced decreases of methamphetamine-induced behaviors.   
Lobeline may be acting to decrease acquisition of methamphetamine-
induced CPP by inducing disruptions in the mechanisms involved in Pavlovian 
learning.  It is currently unknown if lobeline affects these mechanisms.  One would 
expect that if lobeline (3 mg/kg) were impairing the formation of environmental and 
drug reward associations then this dose of lobeline would block the acquisition at all 
methamphetamine conditioning doses, not just the 0.5 mg/kg dose as demonstrated 
in experiment 1.  Since this was not the case, it is unlikely that the results obtained 
here reflect merely a disruption in Pavlovian learning.   
Taken together, the results from the present behavioral experiments 
demonstrate that lobeline has differential effects on the acquisition and expression 
of methamphetamine-induced CPP, as well as methamphetamine-induced 
locomotor hyperactivity.  Lobeline (1 and 3 mg/kg) blocked the acquisition of CPP 
when given in combination with a low dose of methamphetamine (0.5 mg/kg) during 
the conditioning phase.  While only the higher dose of lobeline (3 mg/kg) acutely 
blocked the expression of CPP, a blockade was observed following repeated 
administration of both doses (1 and 3 mg/kg).  As discussed in the introduction, 
amphetamine CPP is not dependent on locomotor activity (i.e. restrained rats will 
acquire CPP).  However, the effect of locomotor hypoactivity during 
postconditioning tests is not entirely clear.  It is unlikely that the hypoactivity 
contributes significantly to the disruption of CPP as a correlational analysis 
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indicated that no relationship exists between locomotor activity and conditioned 
place preference during the postconditioning tests 
While both psychostimulant-induced reward and locomotor hyperactivity are 
dependent on mesolimbic dopamine pathways, they appear to be due to 
independent processes (Carr et al., 1988).  Dissociation between conditioned 
reward and locomotor hyperactivity has been observed previously with 
amphetamine and these behaviors may be regulated by anatomically distinct 
regions of the nucleus accumbens (Sellings & Clarke, 2003).  Sellings and Clarke 
(2003) assessed rats with bilateral 6-hydroxydopamine lesions of the nucleus 
accumbens core or shell on CPP acquisition, CPP expression and locomotor 
activity induced with amphetamine (0.75 mg/kg).  Their results indicate that the 
nucleus accumbens shell meditates amphetamine-induced reward, as lesions in this 
area inhibited acquisition and expression of amphetamine-induced CPP, while 
having no effect on amphetamine-induced locomotor hyperactivity.  In addition, 
lesions of the nucleus accumbens core did not disrupt acquisition or expression of 
amphetamine-induced CPP, but did attenuate amphetamine-induced locomotor 
hyperactivity.     
 The nucleus accumbens shell has been implicated in reward-related 
behaviors.  Previous research has shown that rats will self-administer amphetamine 
directly into this brain region (Hoebel et al., 1983).  In addition, intracranial 
administration of amphetamine into this brain region results in CPP (McBride et al., 
1999; Schildein, Agmo, Huston, & Schwarting, 1998).  Furthermore, the rewarding 
effects of amphetamine can be blocked by 6-hydroxydopamine lesions of the 
nucleus accumbens shell, as well as local administration of D1 or D2 antagonists 
(Hoffman & Beninger, 1989; Spyraki et al., 1982).  These studies indicate that intact 
dopaminergic mechanisms in the nucleus accumbens shell are critically important 
for amphetamine-induced reward.  Based on these results, we hypothesized that 
the effects observed in the current study are a result of lobeline blocking the 
amphetamine-induced increase of extracellular dopamine levels in the nucleus 
accumbens shell.   
To test this hypothesis, we examined the effect of lobeline on 
methamphetamine-evoked dopamine release in the nucleus accumbens shell using 
in vivo microdialysis.  Dopamine levels in the nucleus accumbens shell were 
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increased (~450%) following administration of a relatively low dose of 
methamphetamine (0.5 mg/kg, SC).  In addition, a concomitant decrease in 
extracellular DOPAC (~30%) was evident.  This dose of methamphetamine (0.5 
mg/kg) does not cause neurotoxicity and is a weak inhibiter of monoamine oxidase 
(Miller, Shore, & Clarke, 1980).  It has been suggested previously that the 
methamphetamine-induced decrease in DOPAC may be due to the redistribution of 
newly synthesized dopamine such that it is not available for monoamine oxidase 
degradation (Shimosato, Nagao, Watanabe, & Kitayama, 2003).  In addition, 
methamphetamine-induced reversal of the dopamine transporter presumably results 
in less dopamine available for metabolism to DOPAC in the cytosol. 
The current results demonstrate that lobeline (1 or 3 mg/kg) alone has no 
effect on extracellular dopamine levels in the nucleus accumbens shell, but does 
increase the extracellular concentration of DOPAC (~20%).  These results coincide 
with previous findings indicating that administration of a high dose of lobeline (10 
mg/kg) does not alter extracellular dopamine levels in striatum as assessed with in 
vivo microdialysis in awake rats (Eyerman & Yamamoto, 2005). Unfortunately, dose 
comparisons cannot be made with regard to DOPAC, as this was not reported in the 
study by Eyerman & Yamamoto (2005).  However, another report using in vivo 
microdialysis to assess the effects of lobeline in nicotine pretreated rats in the 
nucleus accumbens core indicated lobeline alone (10 mg/kg, IP) did not affect 
extracellular dopamine or DOPAC (Benwell & Balfour, 1998).  The reason for the 
discrepancy in results between the study by Benwell and Balfour (1998) and the 
current study may be due to neuroanatomical differences between the shell and 
core subregions on the nucleus accumbens (see above).  Finally, when lobeline (2, 
4, 6 nmol at a rate of 2 μl/min for 1 min) is perfused directly into the rat striatum via 
a microdialysis probe, a dose-dependent increase in extracellular dopamine is 
observed; however, DOPAC levels were not reported in this study (Lecca, Shim, 
Costa, & Javaid, 2000).  Since little is known about the diffusion properties of 
lobeline, it is unclear whether the tissue concentrations achieved around the 
microdialysis probe in this latter study are comparable to those achieved via 
systemic administration.  Differences in tissue concentrations of lobeline in the 
target region could account for the differences observed.      
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Previous research using an in vitro superfused striatal slice preparation has 
demonstrated that a low concentration of lobeline (1 µM) has little effect on 
dopamine release, while increasing DOPAC (Teng et al., 1997).  However, higher 
concentrations (100 µM) of lobeline result in dopamine release (Teng et al., 1997).  
The dopamine release observed at the higher concentration is thought to occur 
when dopamine levels in the cytosol exceed the enzymatic capabilities of 
monoamine oxidase (Teng et al., 1997).  Interestingly, pharmacokinetic data 
indicates that when a rat is administered lobeline (4.0 mg/kg; SC) the resulting brain 
concentration is 237 ng/ml (or ~0. 7 μM), indicating that the findings with the lower 
concentrations are more likely relevant for comparison  to in vivo experiments which 
typically use lobeline doses between 0.3 – 10 mg/kg  (Reavill, Walther, Stolerman, 
& Testa, 1990).  Importantly, the brain concentration of lobeline achieved following 
systemic administration of 4.0 mg/kg is similar to the IC50 for lobeline inhibition of 
[3H]DA uptake into vesicles (0.88 μM) in vitro, which is thought to be the primary 
mechanism responsible for the lobeline-induced decrease of methamphetamine-
induced behaviors (Dwoskin & Crooks, 2002; Teng et al., 1997).  The differences 
between in vivo and in vitro findings are probably due to differences in lobeline 
concentration, as the systemic lobeline doses administered in the current study do 
not result in a brain concentration high enough to increase extracellular dopamine 
levels.   
It is well accepted that increases or decreases in extracellular DOPAC are, at 
least in part, the result of altered vesicular storage of dopamine (Eisenhofer, Kopin, 
& Goldstein, 2004). As described in the introduction, amphetamine and lobeline 
have been shown to interact with the vesicular monoamine transporter.  It is likely 
that the lobeline induced increase in DOPAC observed in the current study is due to 
inhibition of dopamine uptake into vesicles, allowing for more cytosolic dopamine to 
be available for monoamine oxidase metabolism to DOPAC (Teng et al., 1998). In 
contrast, the decreases in DOPAC following methamphetamine in the current study 
are likely due to the redistribution of newly synthesized dopamine in such a manner 
that it is not physically available to monoamine oxide for metabolism (Zetterstrom, 
Sharp, Collin, & Ungerstedt, 1988).  It is possible, albeit less likely, that the dose of 
methamphetamine used in the current study inhibits the activity monoamine 
oxidase.  The ability of amphetamine to decrease monoamine oxidase activity is 
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observed following higher systemic doses than those administered in the current 
study (Miller et al., 1980).   
No previous in vivo studies have reported that lobeline administration alone 
results in increased extracellular DOPAC, while simultaneously enhancing the 
methamphetamine-induced decrease.  One possibility for this outcome is that 
lobeline may alter the methamphetamine-induced metabolism of DA to DOPAC in 
the cytoplasm; however, previous in vitro research indicates that lobeline does not 
inhibit monoamine oxidase (Miller et al., 2001).  While the current studies do not 
address this question directly, it is unlikely that lobeline alters the enzymatic activity 
involved in metabolizing dopamine to DOPAC.  During this process, monoamine 
oxidase deaminates dopamine to 3,4-dihydroxyphenylacetaldehype, which is then 
oxidized by aldehyde dehydrogenase to DOPAC (Eisenhofer et al., 2004).   If 
lobeline were decreasing the enzymatic activity of either of these enzymes, a 
decrease in DOPAC would be expected.  Likewise, an increase in the activity of 
these enzymes would be expected to result in an increase in DOPAC.  It seems 
unlikely that lobeline would increase the activity of these enzymes when 
administered alone, but conversely decrease the activity of these enzymes in 
combination with methamphetamine.  Thus, the current results suggest the effect of 
lobeline, as well as the effect of lobeline pretreatment prior to methamphetamine 
administration, is not due to interactions with enzymatic pathway responsible for 
converting dopamine to DOPAC. 
As an alternative explanation, recent studies have suggested that 
psychostimulants can interact with proteins that help regulate and maintain the 
reserve and readily releasable dopamine stores (Venton et al., 2006).  One 
possibility for the current microdialysis study results is that methamphetamine 
induces a redistribution of a portion of the readily-releasable vesicular stores of 
dopamine to a site within the cytosol that renders dopamine not sequestered in 
vesicles to be less likely to interact with monoamine oxidase.  This would result in 
increased dopamine available for reverse transport.  While there is currently no 
information available about interactions of lobeline with other vesicular proteins, 
perhaps methamphetamine changes the dynamics of lobeline’s interactions with the 
vesicular membrane such that lobeline and amphetamine act synergistically to 
redistribute cytosolic dopamine stores.  This could result in further decreases in 
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DOPAC due to a decrease of cytosolic dopamine in a region where monoamine 
oxidase has access to it.  Thus, lobeline may act to redistribute cytosolic dopamine 
pools such that when methamphetamine is available, dopamine is unavailable for 
metabolism.  The mechanisms responsible for these putative effects remain to be 
elucidated. 
No significant effect of lobeline on the methamphetamine-evoked increase in 
extracellular dopamine was observed in the current experiment, although a slight 
decrease was noted at the 60-min time point.  These results are consistent with 
findings reported by Eyerman and Yamamoto (2005) indicating that lobeline (10 
mg/kg) does not acutely attenuate extracellular dopamine levels in the striatum 
following methamphetamine (10 mg/kg).  In contrast, in vitro studies indicate that 
lobeline (0.3 and 1.0 μM) decreases amphetamine (1.0 μM) -evoked endogenous 
dopamine release in rat striatal tissue, indicating a discrepancy between in vivo and 
in vitro effects of lobeline (Miller et al., 2001).  Additionally, a recent study using a 
human embryonic kidney cell system expressing isoforms of both the dopamine 
transporter and vesicular monoamine transporter found that lobeline (100 μM) 
decreases methamphetamine-evoked [3H]DA release (Wilhelm, Johnson, 
Eshleman, & Janowsky, 2008).  Differences among these studies in the effect of 
lobeline on methamphetamine-induced increases in dopamine levels likely reflect 
inherent differences between in vivo preparations using intact animals and in vitro 
preparations examining only a part of the neurocircuitry involved in the drug effects.    
Since lobeline administration decreases methamphetamine-induced 
behaviors, it is possible that lobeline may enhance the peripheral metabolism of 
methamphetamine.  While it is currently unknown if lobeline alters 
methamphetamine brain concentrations, the current results showing that lobeline 
does not alter methamphetamine-induced dopamine release in the nucleus 
accumbens shell argues against a potential pharmacokinetic interpretation.  Based 
on such a pharmacokinetic interpretation, lobeline should have attenuated the 
methamphetamine-induced increase in extracellular dopamine levels. 
Lobeline (3 mg/kg) pretreatment has been shown to decrease 
methamphetamine self-administration and conditioned place preference, which 
suggests that lobeline may be attenuating the effects of methamphetamine 
reinforced behavior via mechanisms other than extracellular dopamine levels in the 
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nucleus accumbens shell.  Another possibility is that lobeline may decrease 
methamphetamine-evoked dopamine release more completely following repeated 
administration.  To date, it can not be concluded with certainty that acute lobeline (3 
mg/kg) is specifically decreasing methamphetamine reward, rather than having non-
specific effects.   Following repeated administration, lobeline (3 mg/kg) more 
specifically decreases methamphetamine self-administration and the expression of 
CPP, while having a decreased effect on other behaviors (i.e. responding for 
sucrose reinforcement or locomotor activity) Harrod et al., 2001).  Thus, 
methamphetamine-evoked increases in extracellular dopamine levels may be 
decreased following repeated lobeline administration.  In any case, the current 
studies emphasis the importance of assessing potential pharmacotherapies 
following repeated administration and including doses that do not affect behavior 
acutely.    
 
Integration with Previous Work 
  Lobeline has been purposed to be a potential pharmacotherapy for 
psychostimulant addiction, attributable in part to its unique pharmacological profile 
(Dwoskin & Crooks, 2002).  Elucidating the mechanisms by which lobeline reduces 
the rewarding effects of psychostimulants would aid in the development of 
pharmacotherapies for the treatment of drug dependence.  It is unlikely that all of 
lobeline’s pharmacological mechanisms are currently known and future research 
will surely uncover additional molecular targets with which lobeline interacts.  
Lobeline has been shown to reduce methamphetamine self-administration in rats, 
indicating it decreases the primary reinforcing effects of methamphetamine (Harrod 
et al., 2001).  The current studies indicate that lobeline is also effective at 
attenuating the conditioned environmental cues associated with methamphetamine 
administration.  In addition, the effects of lobeline on cocaine-induced behaviors 
have also been examined.   Interestingly, lobeline decreases cocaine self-
administration and acquisition of conditioned place preference.  One could 
speculate that nicotinic receptor antagonism, such as that provided by lobeline, may 
be a common pharmacological target for both methamphetamine and cocaine.  
However, additional studies have indicated that mecamylamine does not alter the 
acquisition of methamphetamine self-administration nor does alter stable 
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methamphetamine self-administration.  Taken together, these experiments suggest 
that lobeline is likely decreasing psychostimulant-induced behaviors by altering the 
transport vesicular dopamine stores within the presynaptic terminal.  Since both 
methamphetamine self-administration and conditioned place preference were 
attenuated by lobeline, these results suggest that both the primary rewarding and 
the secondary cue-elicited rewarding effects of methamphetamine involve VMAT2. 
 
Limitations 
Locomotor activity is a commonly reported behavioral measure of 
psychostimulant-induced behavior.  While the automation of many various types of 
behavioral testing apparatuses has provided efficient data collection, it is unclear 
how sensitive each of these automated indices are to different drug treatments.  For 
example, in Experiment 1, lobeline did not cause hypoactivity compared to controls 
following the 4th administration of lobeline when animals were confined to one 
compartment (last conditioning day).  However, hypoactivity was still observed 
following the 5th administration of lobeline when animals were allowed access to the 
entire chamber (postconditioning tests).  Since lobeline has been shown to be 
behaviorally active for ~30 min, these differences in observed locomotor activity 
may be due to the differences in test session length, as the conditioning sessions 
were 30 min and the postconditioning tests were 15 min (Harrod et al., 2001).  
While it is informative to have locomotor activity data during CPP experiments, 
close examination of the testing apparatus and time course effects are necessary 
for comparisons across studies. 
The dose of methamphetamine used for the microdialysis study is on the low 
end of its dose effect curve for most behaviors and results from our laboratory 
suggest that 0.5 mg/kg of methamphetamine is a threshold dose for acquisition of 
CPP.  While it appears that lobeline may have attenuated methamphetamine-
evoked dopamine release, this effect failed to reach significance.  Upon closer 
examination of these groups, it is evident that there was greater variability in the 
peak effects of the methamphetamine-induced increase in dopamine than in the 
lobeline alone groups.  The effects of lobeline may have been masked due to the 
variability in response to methamphetamine at this dose.  One likely contributing 
factor for the variability relates to the probe placement.  Although all probes were in 
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the nucleus accumbens shell, portions of the probe extended beyond the shell.  
Smaller probes and stricter criteria for data inclusion based on probe placement 
may be useful for reducing this variability.  
The current study did not address the possibility that acquisition of lobeline 
CPP may be state dependent.  State dependent learning is the phenomenon in 
which expression of a learned behavior occurs only when an organism is in the 
same physiological or contextual state during recall as it was during learning 
(Overton, 1991).  It cannot be ruled out that lobeline alone is not rewarding in this 
paradigm, as the learned association between reward and environmental cues may 
be state-dependent.  In order to assess this, rats given lobeline during the 
conditioning phase would need to be given lobeline prior to the postconditioning 
test.  It is possible that lobeline CPP would be evident only when rats are in the 
same drug state as they were during conditioning.  Interestingly, like in the current 
study, previous assessment of lobeline-induced CPP did not address the issue, 
indicating that more work is needed (Fudala & Iwamoto, 1986).     
 
Future Directions 
Recent evidence suggests that, in addition to its effect on dopaminergic 
mechanisms, lobeline may function as a mu opioid receptor antagonist (Miller et al., 
2007).  The mu-opioid system is thought to play a role in cue-induced drug-seeking 
behavior, as assessed using cue and drug-primed reinstatement of 
methamphetamine seeking behavior in rats, as well as using sensitization to 
methamphetamine (Anggadiredja, Sakimura, Hiranita, & Yamamoto, 2004).  In 
addition, mu-opioid receptor antagonists have been shown to decrease 
amphetamine-induced increases in dopamine levels in the nucleus accumbens 
(Chiu, Ma, & Ho, 2006; Schad, Justice, & Holtzman, 1996).  It is currently unknown 
if mu opioid antagonists decrease rodent amphetamine self-administration when 
given repeatedly; however, there is some indication that the opiate antagonist 
naltrexone may be useful as an adjunct pharmacotherapy for amphetamine 
dependence in humans (Jayaram-Lindstrom, Wennberg, Beck, & Franck, 2005).  
Further characterization of lobeline’s ability to attenuate the psychoactive effects of 
opiates and how this pharmacological action may interact with methamphetamine 
conditioned reward is warranted.   
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As suggested previously, the effects of repeated administration of lobeline on 
methamphetamine-induced behaviors warrants further investigation.  While 
previous studies have shown that lobeline does not attenuate reinstatement of 
methamphetamine-seeking specifically, only acute effects of this dose were 
assessed (Harrod et al., 2003).  Since repeated administration of lobeline blocked 
the expression of CPP, it is of interest to assess the effects of repeated lobeline on 
drug and cue-induced reinstatement in the operant paradigm.  The current results 
suggest that repeated administration of lobeline may be more efficacious in 
attenuating reinstatement. 
In summary, lobeline has many pharmacological actions that may contribute 
to its potential usefulness as a pharmacotherapy for psychostimulant dependence.  
It may be that a combination of pharmacological actions is necessary for the 
decrease observed in methamphetamine behaviors following lobeline 
administration.  In addition, while self-administration is a standard procedure used 
to assess the direct reinforcing properties of drugs of abuse, differential results may 
be observed when assessing potential pharmacotherapies using the CPP paradigm.  
Perhaps pharmacotherapies that interact with a combination of molecular targets 
may be more effective than highly specific pharmacotherapies in attenuating the 
primary and secondary reinforcing properties of methamphetamine. 
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